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ABSTRACT
Within cellular signaling, protein phosphorylation is the post-translational modification
most frequently used to regulate protein activity. Protein kinases and phosphoprotein
phosphatases generate and terminate these phosphoryl signals, respectively. Chemical
approaches for studying protein phosphorylation and the roles of phosphoproteins include
photolabile caged analogs of bioactive species. Caged compounds are ideal chemical probes for
studying cellular signaling because they afford researchers spatial and temporal control over the
release of targeted effector molecules. Ligands or proteins involved in signal transduction can be
chemically caged and subsequently irradiated to release a concentration burst of a specific
species, allowing the downstream effects to be monitored without disrupting other aspects of the
system.
The syntheses and applications of caged phosphopeptides and phosphoproteins have been
developed and detailed within this thesis. Two methods to synthesize 1-(2-nitrophenyl)ethyl
caged phosphopeptides were developed. These peptides demonstrated good quantum yields of
uncaging as compared to literature values of other ortho-nitrobenzyl derived caged compounds.
A study in which these caged phosphopeptide tools yielded seminal information about the 14-3-3
protein family's involvement in cell cycle control successfully demonstrated the unique utility of
these probes. Furthermore, the synthesis that allowed the extension of the nonsense codon
suppression methodology to include caged phosphoproteins was developed. The three most
commonly phosphorylated amino acids (serine, threonine, and tyrosine) were each incorporated
into a test protein in their caged phosphorylated form. Toward studying cell motility, caged
phosphoserine was incorporated into position 153 of mVASP for use in live cell assays.
Thesis Advisor: Barbara Imperiali
Title: Class of 1922 Professor of Chemistry and Professor of Biology
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Chapter 1
Introduction
Portions of this chapter have been submitted for publication to Trends in Cell Biology.
1-1. General Introduction
Cellular signaling pathways integrate the actions of a myriad of ligands, substrates and
proteins that comprise extremely complex networks of forward signals, feedback loops, and
modulatory actions. Defining the spatial and temporal roles of the participants in the signaling
cascades of living systems is a major challenge in cell biology. Since signaling molecules are in
a constant state of flux, experimental approaches that afford information on the temporal and
spatial dynamics of the components are extremely desirable. In this context, chemically-driven
strategies including small molecule inhibitors and activators as well as biotic and abiotic
chemosensors provide a powerful complement to the robust genetics-based methods that have
enabled the identification of numerous pathways in living cells.' Chemical probes for the study
of signal transduction networks can be of either exogenous or endogenous origin. Endogenous
probes, including designed sensors based on the Aequoria victoria fluorescent proteins (AFPs),
are expressed and used within cells, while exogenous probes are prepared ex vivo and may be
introduced into living cells via microinjection, transfection, or through utilization of protein
transduction domains.
Within cellular signaling, protein phosphorylation is the most abundant post-translational
modification for the regulation of protein activity.2 ' 3 Protein kinases and phosphoprotein
phosphatases generate and terminate these phosphoryl signals, respectively.4 Chemical
approaches for studying protein phosphorylation and the roles of phosphoproteins include
photolabile caged analogs of bioactive species (Figure 1.1).
O 0
O-P-O --O-- CAGE
rOH kinase hv 0 0
......... phosphatase ........ 
Figure 1.1. Phosphoregulation of proteins. Kinases append phosphoryl groups to hydroxyl side chains,
while phosphatases remove them. Alternatively, a caging group on a phosphate can be removed with
light to reveal the phosphoprotein.
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Caged compounds are ideal chemical probes for studying cellular signaling because they
afford researchers spatial and temporal control over the release of targeted effector molecules.
Ligands or proteins involved in signal transduction can be chemically caged and subsequently
irradiated to release a concentration burst of the specific species, allowing the downstream
effects to be monitored without disrupting other aspects of the system. For a brief discussion of
caging and the history of the technique, please see Section 1-7. The most frequently implemented
caging groups in biological experiments are derived from the ortho-nitrobenzyl protecting group,
discussed in further detail below (Section 1-8). Other caging groups used in biological studies
include hydroxyphenacyl derivatives, coumarins, and cinammic acid derivatives.5 9 Several
examples of recently developed caged signaling molecules are discussed here with an emphasis
on those used for studying phosphorylation in signal transduction.
1-2. Caged Small Molecules, Peptides, and Proteins
More than two decades have passed since the original caging experiments of ATP and
clivalent cations were published.0-'2 Currently, multiple reports of caged neurotransmitters,
peptides and fulllength proteins are present in the literature. These studies revealed information
in space and time domains inaccessible by other methods. 3-' 7
Both caged L-glutamic acid'8 and caged D-aspartic acid9 have been synthesized and used
to study the effects of each stimulant on its cognate receptor. The molecular mechanism of the
high affinity glutamate transport process is difficult to study with traditional rapid solution
exchange techniques due to poor time resolution. It was found that L-glutamic acid caged on the
y-carboxylate with the c-carboxynitrobenzyl moiety had desirable photochemical properties with
a half-life of 21 jis and quantum yield of 0.14.8 Taken together, these parameters allowed the
time-resolved study of the activation of glutamate receptors, which have a lifetime for the "open"
species on the 1 ms timescale. In a further example of caged neurotransmitters, D-aspartic acid
was caged in order to study the effect of D-aspartic acid on glutamate transport, which is a highly
pH dependent process. The rate and quantum yield of uncaging is also dependent on pH. An -
carboxynitrobenzyl caged D-aspartic acid was synthesized that had good uncaging kinetics at
various pH values which was valuable for further synaptic studies. 19
Caged peptides can be used as masked inhibitors of protein functions that are regulated
by phosphorylation. After introduction of a caged inhibitory peptide, the steady state of the
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system is not perturbed; therefore, the immediate downstream effects of sequestering a targeted
protein can be monitored upon uncaging. In a study on eosinophil cell motility two caged
tyrosine peptide inhibitors of myosin light chain kinase (MLCK) were employed to reveal that
MNLCK is globally central to whole cell movement.20 Flash photolysis allowed the peptides to
rapidly sequester the MLCK in the system, and it was observed that cell motility significantly
decreased, thus demonstrating that MLCK is essential in cell migration signaling. Whereas
former studies had been performed on the minute to hour timescale, the observations described
were made in the previously inaccessible time domain of seconds.
Several amino acid side chains in full-length protein have been caged using various
methods. Approaches range from non-specific labeling of nucleophilic residues to cysteine
scanning-mutagenesis trials to site-specific incorporation of caged amino acids (see reviews 13,
14, 16, 17). In a more recent study, thymosin 34 (TO4) was non-specifically caged on lysine
residues, and observations from studies with its use were compiled to formulate a mechanical
model of cell turning in locomoting keratocytes (Figure 1.2).21 Computer simulations predicted
the concentration of locally uncaged T4 necessary within a locomoting cell to cause a
biological response without loss of effect due to diffusion. Indeed, upon local photolytic release
of TP4, cell movement changed dramatically and appeared temporarily imbalanced relative to
control cells. Using caged Tf34 allowed both spatial and temporal release of the protein, yielding
new information about its functional role in motile cells.
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1-3. Caged Phosphopeptides
As mentioned above, essential early studies demonstrated that simple caged peptides
allow phenotypic observations to be made in the previously inaccessible time domain of
seconds.3 ' 20 More recently, methods to synthesize caged phosphopeptides have been developed
for the purpose of studying phosphopeptide-binding domains (Chapter 2).22 23 With these new
chemical tools, the global temporal function of the entire 14-3-3 family on cell cycle regulation
was examined (Chapter 3).24 Photoliberation of a phosphopeptide designed to bind to all
isoforms of 14-3-3 caused synchronized cells to exhibit several unique characteristics compared
to control cells: increase in programmed cell death, loss of G2/M-phase progression, and loss of
S-phase checkpoint function (in cells with DNA damage) (Figure 1.3). The temporally controlled
release of the caged phosphopeptide enabled the observation that 14-3-3 is necessary for mitotic
entry of normally cycling cells and it is essential for S-phase checkpoint function in cells with
DNA damage.
14-3-3/ '
Figure 1.3. Caged
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14-3-3. After brief
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1-4. Caged Constitutively Active Kinase Substrate
Some kinase substrates are inactivated by phosphorylation and activated by
dephosphorylation. The LIM-kinase substrate cofilin is one such protein: in the
unphosphorylated form, cofilin binds to F-actin and severs the filaments to create barbed ends
and modulate cell motility. LIM-kinase phosphorylates serine-3 of cofilin to render the protein
inactive.25 Recently, a constitutively active mutant, cofilin Ser3Cys, was prepared and it was
demonstrated that exposure of this mutant to F-actin caused filament severing and
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depolymerization in vitro. In order to regulate the cofilin activity, the mutant protein was caged
via selective chemical modification with the a-carboxynitrobenzyl group at the unique cysteine
at position 3. In these studies, the ac-carboxylate substituent in the caging moiety enhanced the
efficiency of uncaging while simultaneously mimicking the inactive phosphorylated cofilin
(Figure 1.4). In the presence of caged cofilin Ser3Cys, F-actin was as stable as in the control
system. However, upon irradiation, 80% of severance activity was restored to cofilin Ser3Cys.
This caged mutant protein was further evaluated in live cells and the studies revealed that active
cofilin is essential for many aspects of cell motility.26 Cofilin aided in G-actin polymerization in
vivo: global uncaging of cofilin Ser3Cys increased free barbed ends, F-actin content, and cell
locomotion, while local uncaging generated lamellipodia and determined the direction of cell
migration. Since LIM-kinase cannot phosphorylate the Ser3Cys mutant, the effect of cofilin
persisted for the duration of the cell monitoring. For these studies, this effect was advantageous
since the active species is the unphosphorylated protein. However, for situations in which the
phosphorylated species is the active form of the protein, it is desirable to have access to the
caged phosphoprotein.
............................................................................-.
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Figure 1.4. Caged mutant cofilin (Ser3Cys) reveals a role for cofilin during cell motility.
1-5. Caged Phosphothioproteins
Thiophosphoryl derivatives of serine, threonine and tyrosine can act as phospho-amino
acid analogs in biological studies of protein phosphorylation. Thiophosphoryl groups
demonstrate distinct properties in cellular systems: they are more nucleophilic and more resistant
to hydrolysis by phosphatases compared with native phosphoryl groups.27 Recent work has
extended the strategy for caging thiophosphopeptides to the preparation of full-length caged
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thiophosphoproteins.6, 7 28 The semi-synthetic approach involves thiophosphorylation of a serine,
threonine, or tyrosine residue using an appropriate kinase in the presence of ATP(y)S and a
thiophilic divalent cation, such as Co2+ (Figure 1.5).7 The caging group is then introduced by
taking advantage of the nucleophilicity of the thiophosphate sulfur to displace bromide from the
electrophile. In these studies, it was found that the hydroxyphenacyl caging group had superior
photosensitivity (Box 2) to the o-nitrobenzyl group on thiophosphate.7 At the protein level, a
caged thiophosphothreonine-197 variant of PKA was prepared by semi-synthesis and then
activated via UV irradiation.6 Upon uncaging, 85-90% of protein activity was restored,
corresponding to a 15-fold increase in activity over the caged precursor, which is significant for
potential biological studies. Caged thiophosphoproteins are useful reagents for studying signal
transduction due to the stability of the thiophosphates towards endogenous phosphatases.
However, the enzyme-catalyzed thiophosphorylation reaction is not general and multiple kinases
and divalent cations must be screened for the semi-synthesis of each new caged peptide or
protein target.
O H O H - - - - - - - - - - - - - - - -
0 0 0 0ATPI(y)S B--r~jo ,f OATP(y)S O-r-S Br4 o-S-S O oNp_5 mimic -P-O
OH divalerit cation 0 hv o
r ; kinase r _ K 
]Figure 1.5. Caged thiophosphoproteins mimic phosphoproteins upon uncaging.
1-6. Caged Phosphoproteins
Recently, expressed protein ligation and semi-synthesis has been used to prepare the
caged phosphoprotein Smad2, which was caged on two phosphoserines at the C-terminus (Ser
465 and Ser 467) (Figure 1.6).29 Under native conditions, transforming growth factor 3 (TGF-3)
phosphorylates two serine residues on Smad2, which then causes disengagement from the
cytosolic retention factor SARA and allows homotrimerization of Smad2 and nuclear uptake.
The caged phospho-Smad2 binds to SARA and cannot homotrimerize. However, upon brief and
intense irradiation, the phospho-Smad2 is uncaged and released from SARA thereby initiating
homotrimerization and nuclear localization.29 These experiments demonstrate the application of
native chemical ligation for the preparation of caged phosphoproteins that are amenable to semi-
synthetic strategies.
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Figure 1.6. Caged phospho-Smad2 acts like native phospho-Smad2 after UV-irradiation. See reference 29.
An alternative general approach for the synthesis of caged phosphoproteins has recently
been introduced which allows for the replacement of a single residue in native proteins with a
caged phospho-amino acid (Chapter 4).30 A novel phosphitylation reagent enabled the chemical
synthesis of an appropriately protected amino acid derivative for the generation of an amino-acyl
tRNA charged with the caged phospho-amino acid. Incorporation of the unnatural amino acid
into proteins was then accomplished via the nonsense codon suppression methodology using an
in vitro translation system. This strategy was used for the semi-synthesis of the cell motility
protein mVASP with caged phosphoserine at position 153 (Chapter 5). Gel shift analysis
demonstrated that the caged phosphoprotein behaves as the unphosphorylated protein, and upon
UJV irradiation the uncaged protein migrates adjacent to the phosphorylated control. This
directed approach should allow for the substitution of any serine, threonine, or tyrosine residue in
full-length proteins with caged phosphorylated analogs provided that the in vitro translation
efficiency is acceptable.30 The recent developments in the availability of full-length caged
phosphoproteins, in addition to the aforementioned caged analogs, should further advance
studies exploiting the caging technology in the realm of signal transduction.
1-7. History and Requirements of Caging Groups
Caged compounds are molecules that include a photolabile mask on an essential
functional group. With UV irradiation the mask is removed and the liberated molecule can exert
its effect on the system.' ° Photolabile protecting groups have been in use in organic synthesis for
many years.3 Due to the hydrophobicity of photolabile groups, they were first used in biological
systems to aid in cell membrane permeation of caged nucleotide analogs which could
subsequently be uncaged in living cells.32 The term "caging" was coined when a photolabile
protecting group was placed on the y-phosphate of ATP. The ability of the caged compound to
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release ATP upon irradiation (be "uncaged") was characterized by Na,K-ATPase consumption
and Na+ efflux from cells via the Na:K pump.'0 The caged ATP could not be hydrolyzed by the
Na,K-ATPase until after illumination to remove the caging group. Additionally, caged ATP had
no effect on the Na:K pump in cells until after photolytic removal of the caging group. This
study set the precedent for the future of caging in biological studies. In addition to control over
the release of the effector molecule, caged compounds enable complete intracellular distribution
of the target compound, 4 thus allowing each cell to serve as its own control (before and after
photolysis).20 Use of caged compounds circumvents genetic compensation effects often observed
in single knock-out studies.24
There are several key requirements of a caged compound to be successful in biological
studies: (i) the caged compound should neither agonize nor antagonize the system, (ii) after
irradiation, the compound should be released rapidly and in high yield, (iii) the photo-byproducts
should be inert within the system, and (iv) the photolytic conversion must be accessible in an
intracellular environment such that the downstream events can be immediately monitored.'
Other factors to consider include the quantum yield of uncaging, the wavelength of excitation,
and the extinction coefficient of excitation (see below). A caging group can mask a functional
group through two different strategies: steric bulk and electronic induction. The steric bulk
strategy involves using a caging group to spatially block an interaction prior to photoliberation.
The electronic induction strategy employs a caging group to withdraw or distribute electron
density such that a key interaction cannot take place before photolysis. A study in which caged
cation chelators were synthesized to tightly bind divalent calcium upon irradiation illustrates
these two different strategies.' 2
1-8. Caging Groups and Photophysical Properties
The most commonly used caging groups in biological studies are based on the ortho-
nitrobenzyl moiety. The o-nitrobenzyl group is inert within living cells, has a good quantum
yield of uncaging () on the microsecond-millisecond timescale, and can be excited with near-
visible UV light (> 350 nm), which does not cause radiative damage to cells. Additionally, when
attached to biological molecules, o-nitrobenzyl compounds and the corresponding photo-
byproducts are water-soluble at physiological concentrations. Original studies demonstrated that
intracellular thiols (e.g., glutathione) act as effective scavenging agents for the nitrososbenzene
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photo-byproducts.° 33 The proposed mechanism of photolytic release for o-nitrobenzyl ethers is
shown in Scheme 1.1 where X is the key functional group of the biological effector.33
Scheme 1.1. Photochemical decomposition of o-nitrobenzyl caged molecules.
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The cyclization and subsequent breakdown of the aci-nitro intermediate has been
spectroscopically monitored to determine the rate of release of the product. More recent research
suggests that hemiketal formation may be involved during the photolytic release of 1-(2-
nitrophenyl)ethyl ethers.34 The released nitroso-acetaldehyde (R = H) was found to be much
more reactive in a biological context than released nitroso-acetophenone (R = CH3), ° likely due
to the higher intrinsic reactivity of the aldehyde toward nucleophiles.
It is significant to note that the quantum yield of uncaging is a measure of photoliberation
efficiency and not a measure of the rate of uncaging. The quantum yield describes how many
caging groups are released for every photon absorbed by the group. The speed of the breakdown
of the excited species to release the effector molecule determines the rate of uncaging. The o-
nitrobenzyl groups have uncaging rates on the microsecond timescale. 8 33
Furthermore, the intensity of the light source can have a significant effect on the apparent
rate of uncaging of a sample. For example, a light source sending a large number of photons
focused on the sample, such as a laser, will appear to have a faster rate of uncaging than a more
diffuse source, such as a UV lamp. The actual rate of the breakdown of the photo-excited state
does not change between such circumstances; however, the large number of photons from the
laser will proportionally uncage more molecules than the UV lamp, and thus analysis on the
minute time scale will appear that the laser is uncaging the sample more quickly.
Another important physical characteristic for selecting a caging group is the product of
the quantum yield and the extinction coefficient at the excitation wavelength (-E) or the
photosensitivity of the caging group.7 It is not uncommon for a caging group to have an excellent
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A and a poor , and vice versa. Therefore, the product of these values is critical to selecting an
efficient caging group.
1-9. Selection of the 1-(2-Nitrophenyl)ethyl-Cage for Phosphopeptides and Phosphoproteins
For the purpose of synthesizing caged phosphopeptides and phosphoproteins, the o-
nitrobenzyl derivative 1-(2-nitrophenyl)ethyl moiety was chosen. There was abundant literature
precedent for use of the o-nitrobenzyl derivatives at the time of the initial syntheses. The 1-(2-
nitrophenyl)ethyl group was selected because it releases a ketone rather than an aldehyde as a
photo-byproduct. Groups without any substitution at the benzylic position release an aldehyde,
which is highly reactive in the cellular environment (as described in Section 1-8). The 1-(2-
nitrophenyl)ethyl group has a maximum absorption at = 259 nm, with a strong extinction
coefficient (Em = 5,700 M'cm-1 ).3 5 The absorption spectrum is broad, and thus the aromatic
group still absorbs significantly at high-end UV ( = 365 nm). Caging moieties can been
modified on the aromatic ring to include electron donating substituents which help to red-shift
the absorption band; for example, the 4,5-dimethoxy-2-nitrobenzyl group can be uncaged with
light as far out as k = 420 nm. However, the 4,5-dimethoxy-2-nitrobenzyl derivative suffers from
a poorer quantum yield. For the studies described in this thesis, uncaging with k = 365 nm was
sufficient and thus the 1-(2-nitrophenyl)ethyl-caging group, which had strong literature
precedent, was employed.
1-10. Embarkment
As the number of tools for studying signal transduction grows, the amount of information
mined from the use of these tools is amplified. Currently available tools for studying signal
transduction have already provided significant information about the behavior of signaling
molecules in cell lysates and in living cells that would not be possible by other means. Chemical
tools have the inherent ability to be modified by the researcher; the growing feasibility of the
required manipulations to prepare probes is further increasing their availability. Therefore, the
advancement of chemical tools to study signaling networks will lend heavily to the foundation of
understanding how cells function.
Caged compounds afford a researcher spatial and temporal control over the release of an
effector molecule in a biological system, and studies with these probes have just scratched the
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surface of understanding cell signaling pathways. In particular, for the study of phosphorylation
regulated signaling, caged phosphopeptides and phosphoproteins are tools that will yield a great
amount of information about the function of phosphorylated species in real time. Within this
thesis, two methods to synthesize caged phosphopeptides are described (Chapter 2). A seminal
example in which these tools yielded information about cell cycle control is then described in
detail (Chapter 3). The synthesis that allowed extension of the caged phosphopeptide
methodolgy to caged phosphoproteins is also described (Chapter 4). Finally, the progress toward
application of caged phosphoproteins in live cell assays is also discussed (Chapter 5).
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Chapter 2
Two Synthetic Methods for Caged Phosphopeptides
Portions of this chapter have been published in Organic Letters' and Journal of Organic
Chemistry2 as noted in the text. Copyright © 2002 and 2003, respectively, American Chemical
Society.
Introduction
Two synthetic methods that give general access to peptides incorporating the caged
phosphoserine moiety are described in this chapter. Both methods make use of a novel
phosphitylation reagent incorporating the 1-(2-nitrophenyl)ethyl caging group. The first method
is an interassernbly approach that enables the synthesis of caged phosphopeptides without
oxidation-sensitive residues C-terminal to the caged phosphoserine.' The second method is a
building block approach to synthesize any caged phosphopeptide within the limits of Fmoc-SPPS
(N-fluorenylmethoxycarbonyl solid phase peptide synthesis).2 While the interassembly approach
is limited to laboratories capable of performing organic chemistry manipulations on a solid
support, the building block approach is accessible to any scientist with peptide synthesis
capabilities. Using these methods, several peptides were synthesized and characterized as targets
for biological studies. Furthermore, quantum yield measurements were performed and it was
found that all the peptides had quantum yields comparable to literature values for other
compounds including similar ortho-nitrobenzyl derived caging groups.
Results and Discussion
2-1. Interassembly Approach
Initially, a "consensus sequence" peptide, CS, was developed to test the chemistry of the
interassembly methodology. A literature search was performed on the substrate sequences of the
serine kinases. he information was used to develop a CS that incorporates the amino acid
residues that most commonly flank the active phosphoserine in the protein. One study attempted
to compile such a consensus for sequence recognition by the protein kinases which act upon the
serine/threonine and tyrosine kinases.3 The residues surrounding the amino acid that is
phosphorylated during signal transduction vary considerably; however, it is known that proline
and arginine residues are frequently found proximal to the recognition site. Most often, proline
appears at the (n-tl) site, and arginine appears at the (n-2) and/or the (n-3) site.3 Therefore, the
"consensus sequence" Arg-Arg-Gly-Ser-Pro-Gly was designed in order to test the chemistry of
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synthesizing a peptide with caged phosphoserine (Ser is the kinase substrate residue). It is
significant to note that several residues commonly employed in Fmoc-SPPS have side chains that
require stringent deprotection steps, and it was important to test the stability of the photolabile
caging group to these conditions. One of the more difficult residues with which to work in Fmoc-
SPPS is arginine: the nucleophilic guanidinium group requires stable protection to prevent side
reactions. Of the available arginine protecting groups, the benzyl-sulfonyl- derivatives, such as
Pbf (2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-), are most commonly used for their
relative ease of removal, but even these groups require several hours of agitation in greater than
90% trifluoroacetic acid (TFA) for deprotection. This initially presented the challenge of
selecting a caging group stable to such harsh conditions. In addition to the favorable biological
properties of the ortho-nitrophenylethyl group presented in Chapter 1, the caging group is stable
to strong acid and base conditions, making it ideal for use in Fmoc-SPPS.
Scheme 2.1 Synthesis of 0-1-(2-nitrophenyl)ethyl-O'-l-cyanoethyl-N,N-diisopropylphosphoramidite, 4.
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The initial method to synthesize caged phospho-peptides was termed an interassembly
approach of Fmoc-SPPS. An interassembly approach is one in which a non-native moiety is
introduced into a growing peptide chain while it is still attached to the resin. Literature precedent
demonstrated that phosphopeptides can be synthesized in such a manner using a mixed
phosphoramidite.4 Additionally, it has been reported that mono-protected phosphates are ideal
for Fmoc-SPPS. 5 Therefore, a new phosphitylation reagent was synthesized to incorporate a 1-
(2-nitrophenyl)ethyl caging group, as seen in Scheme 2.1. Briefly, 2-nitroacetophenone (1) was
reduced with sodium borohydride to the corresponding racemic alcohol, 2. The chloro-
substituent of the DNA synthesis reagent 3 was then substituted with the alcohol 2 to afford the
mixed phosphorarnidite 4. The racemic benzylic methyl on the caging group should not affect
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uncaging. Experiments performed using such a racemic mixture of the caging group form the
foundation of uncaging studies with a ortho-nitrophenylethyl caged phosphoryl group.6
Scheme 2.2 Synthesis of caged phosphopeptide via the interassembly approach.
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Phosphoramidite 4 was incorporated into a growing peptide chain as shown in Scheme
2.2. A peptide was synthesized on solid support using standard Fmoc-SPPS procedures, and the
target serine residue was incorporated without side chain protection (5). The serine was then
phosphitylated with 4 activated by 1-H tetrazole to afford the phosphite peptide 6. The tervalent
phosphorus* species was then oxidized to the pentavalent species 7 using meta-
cholorperoxybenzoic acid (m-CPBA). When the Fmoc-group on the N-terminus of the peptide
was removed with basic conditions for chain elongation, the temporary cyanoethyl protecting
group on the phosphate was concurrently removed (8). The caged phosphate was stable to further
Fmoc-SPPS and stringent peptide cleavage conditions: greater than 90 % trifluoroacetic acid
(TFA). Peptides with caged phosphothreonine or caged phosphotyrosine were also accessible by
using similar methodology.'
* Throughout the text, the term tervalent phosphorus refers to phosphorus with four pairs of
electrons, even though it may be tricoordinate. The pentavalent species is that with five pairs of
electrons, and it is often tetracoordinate. See reference 7.
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Figure 2.1. 3 P MAS NMR of
peptide on AM-PS resin. Shifts
are shown in b (ppm) relative to
H3PO4 ( = 0 ppm). See
reference 1.
a) Free serine, 5.
b) Phosphite, 6.
c) Phosphate, 7.
d) Deprotected phosphate 8.
While the peptide depicted in Scheme 2.2 has unspecified side chains flanking the caged
phosphoserine residue, the different phosphorus states corresponding to the numbers under each
peptide can be visualized using 31P Magic Angle Spinning Nuclear Magnetic Resonance
spectroscopy (MAS-NMR). The peptide cpSer-Pro-Gly was synthesized on high loading
aminomethylated polystyrene resin (AM-PS) and the progression of the reactions was monitored
by the phosphorus NMR shifts. As seen in Figure 2.1, the free serine peptide has no 3 1 p signal.
Upon phosphitylation, there is a 3 1 p shift characteristic of a tricoordinate, tervalent phosphite
species.7 After oxidation, the 31 p signal shifts to the characteristic range of a tetracoordinate,
pentavalent phosphate. Finally, upon removal of the cyanoethyl and Fmoc groups, a slight shift
in the 3 1 p spectrum is observed, though it remains in the spectral region of a phosphate species.
In addition to the MAS-NMR measurements, final peptide products were cleaved from the resin
and their identities were confirmed by reversed phase High Performance Liquid Chromatography
(HPLC) and Electrospray Ionization Mass Spectrometry (ESI-MS). It is significant to note that
only those peptides with tetracoordinate, pentavalent phosphorus could be identified by HPLC
and MS. The phosphite intermediate is unstable to the peptide cleavage and analysis conditions,
and thus MAS-NMR was employed as a method of monitoring reaction progression.
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2-2. Building Block Approach
While the interassembly approach affords access to a wide variety of caged
phosphopeptides, it contains two potential limitations. First, sequences that contain oxidation-
sensitive residues (such as methionine or tryptophan) C-terminal to the caged phosphoserine,
would be oxidized upon transformation of the tervalent phosphorus to the pentavalent species
(Scheme 2.3). Additionally, laboratories interested in peptide tools for studying phosphorylation
that are not equipped to perform the organic chemistry manipulations on the resin cannot utilize
the interassembly approach. In order to circumvent these limitations, a building block approach
was developed such that any caged phosphopeptide can be synthesized within the limits of
Fmoc-SPPS.
Scheme 2.3 Oxidation of sensitive residues on bead.
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The synthesis of the caged phosphoserine building block incorporates the same
phosphoramidite reagent as the interassembly approach. As seen in Scheme 2.4, the Fmoc-and
trityl-protected serine derivative 9 was first transformed into the tert-butyl ester 10 using tert-
butyl trichloroacetimidate. The hydroxyl side chain was then deprotected in mild acid to afford
11. The serine was phosphitylated using the aforementioned reagent (4) and subsequently
oxidized with mCPBA to give the fully protected derivative 12. Finally, the free acid 13 was
generated by treatment with acid at room temperature. It is important that the deprotection is run
at 23 C or warmer; lower room temperatures resulted in failed reactions. Caged
phosphothreonine and caged phosphotyrosine building blocks were also accessible using this
general synthetic route with minor alterations to the procedure.2 These building blocks have been
successfully incorporated into multiple polypeptide chains within the limits of standard Fmoc-
SPPS.
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Scheme 2.4 Synthesis of Na-Fmoc-phospho-(O- 1-(2-nitrophenyl)ethyl-O'-3-cyanoethyl)-L-serine, 13.
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2-3. Peptides Synthesizedfor Biological Targets
Following successful incorporation of the caged phosphoserine moiety into the CS,
creating cpCS, several other peptides were synthesized for potential biological experiments in
collaboration with other research groups.
cpERK
cpPax
0
NH2
i\OH
Figure 2.2. Caged phosphopeptides cpERK and cpPAX were synthesized and characterized for use
in biological studies.
Two peptides, cpERK and cpPax (Figure 2.2), were synthesized and characterized,
though ultimately were not used for biological studies. cpERK was designed to bind to the
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family of extracellular signal-regulated kinases, ERKs. ERKs make up a group of mitogen
activated protein kinases, MAPKs, and have been implicated in multiple signaling pathways,
including those implicated in cell motility, differentiation, and proliferation. Concerning cell
motility, ERKs are thought to be involved in the Integrin adhesion pathway, closely linked to
calpain function. M-calpain (the isoform that requires near millimolar concentrations of Ca2+ for
proteolytic activity in vitro) may be involved in growth-factor-mediated motility, or
chemokinesis. It has been proposed that epidermal growth factor (EGF) activates
homodimerization of the EGF receptor (EGFR), which in turn activates phosphorylation of ERK.
The phosphorylated ERK can then phosphorylate serine 50 in M-calpain, placing M-calpain in
the active form, which is necessary for tail de-adhesion in cell motility. 8 With a caged phospho-
derivative of an ERK antagonist peptide, we aimed to "turn off' chemokinesis when the cage is
removed by photolysis: the phosphopeptide would block ERK's ability to activate M-calpain
and halt cell de-adhesion. The substrate peptide Pro-Leu-cpSer-Pro-Ala-Lys-Leu-Ala-Phe-Gln-
Phe-Pro (cpERK) was recommended9 because the dodecamer contains the core ERK recognition
motif, Pro-Leu-Ser-Pro, and an ERK docking motif, Phe-Xaa-Phe-Pro.
The cpPax peptide was designed to mimic a portion of paxillin, a 68 kDa focal adhesion
protein involved in multiple aspects of cell migration and Integrin binding. It is a multi-domain
protein that binds to several structural and regulatory partners, functioning as a scaffold for
recruiting other proteins involved in cell adhesion, cell motility and growth control.'° The cpPax
sequence was taken from Serl69-Thrl186 of human paxillin, with Serl78 as the phosphorylation
target. Phosphorylation of several tyrosine residues is important for downstream binding
interactions, but the immediate function of the phosphoserine residues on Paxillin remains
unknown to date. For the purpose of in vitro experiments, a caged phospho-, a phospho- and a
free serine peptide analog of cpPax would have been conjugated to sepharose beads via an N-
terminal cysteine residue and used in protein pull down assays to determine the ability to bind
paxillin-binding partners.11
A third peptide, cpRSLP (Figure 2.3), was synthesized and characterized for studying the
family of 14-3-3 proteins in a collaborative effort with the Yaffe Lab (M. I. T. Department of
Biology). The biological design and implications of this peptide substrate are discussed in detail
in Chapter 3.
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Figure 2.3. Peptide synthesized and characterized for studying the 14-3-3 protein family, cpRSLP.
2-4. Quantum Yield Measurements
The quantum yields of uncaging, 1, for the peptides were found to be comparable to
literature values, and apparently peptide dependent. It was possible to measure the quantum
yield by comparing the loss of caged peptide to the loss of a standard with a known quantum
yield that was subjected to the same conditions.' 2 As explained in the literature, by taking into
account the A350 values of the standard and the sample and then quantifying the amount of
standard and sample lost by photolysis, the quantum yield of the sample may be calculated using
the following equation:
(sample -= standard %Asample x A, standard
%Astandard A35 0 sample
The standard used for these measurements was 1-(2-nitrophenyl)ethyl-phosphate, which has a
known quantum yield of 0.54.12 In brief, the caged phosphate or caged phosphopeptide was
irradiated for 15 seconds in order to uncage 10 to 20% of the peptide. All samples were
photolyzed at X = 365 nm and an intensity of 7330 [tW/cm 2 in a glass vessel with a mm path
length. The amount of caged compound lost after irradiation was quantified by reverse phase
HPLC analysis. Using a photochemically inactive internal standard of 1 mM inosine in each
sample, the area of caged compound on each HPLC trace was normalized to that of inosine at t =
0 and t = 15 s post irradiation. All solutions were made in dH2O, pH 7.1, with 5mM dithiothreitol
(DTT) to prevent side reactions of the photochemical by-product, nitrosoacetophenone, with the
caged or uncaged samples (Chapter 1). Each experiment was performed in triplicate. The
quantum yields of those peptides characterized are shown in Table 2.1.
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Table 2.1. Quantum yield of uncaging for various peptides.
Peptide Quantum Yield (0)
cpCS: Ac-RRGcpSPG-CONH 2 0.21
cpERK: Ac-PLcpSPAKLAFQFP-CONH2 0.26
cpRSLP: Ac-MARRLYRcpSLPAKK-CONH2 0.42
Key cpS: caged phosphoserine.
Although the of all the peptides tested falls within the range of reported literature
values for the 1-(2-nitrophenyl)ethyl moiety, it appears that is dependent upon peptide
sequence. It is possible that different residues flanking the caged phosphoserine create
significantly different remote environments, such that the leaving group (the phospho-peptide)
becomes better or worse depending on those flanking residues. However, these residues do not
yield through-bond effects on the phosphopeptide. It is also possible that those same residues
may stabilize or destabilize the aci-nitro-intermediate discussed in Chapter 1; a stabilized
intermediate would likely result in a reduced quantum yield. However, these explanations are
only speculation, and no further experiments were performed.
In addition to measuring the quantum yield of the peptides, several light sources with
different power outputs were tested to investigate the effect of light intensity upon the rate of
uncaging. Note that 1 only measures the relative efficiency of uncaging, and not the rate of
uncaging. cpERK was subjected to different light sources with varying intensity as shown in
Table 2.2. Time course experiments were performed to determine the amount of cpERK
uncaged by the various sources, as illustrated in Figure 2.4.
Table 2.2. Light sources tested for uncaging.
Source Wavelength Power at the Sample
Transilluminator* 365 nm 7.3 mW
Fluorometer t 300 nm 3.0 mW (estimate)
N 2 Laser A 337 nm 3.0 mW
N]2 Laser B 337 nm 6.0 mW
* Ultra Violet Products (UVP) High Performance Ultraviolet Transilluminator
Jobin Yvon Horiba FluoroMax-P Fluorometer
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Figure 2.4. Amount of caged peptide lost
by photolysis from various light sources.
Samples of cpERK (274 M with 500 [tM
inosine, 500 tM DTT) were irradiated with
various sources and aliquots removed for
analysis by reverse phase HPLC. The
amount of cpERK removed by uncaging is
plotted along the Y-axis.
0 1 3 5 7 9
Irradiation Time (minutes}
The inconsistent data for the Laser B, which appears to demonstrate rapid uncaging
followed by recaging of the peptide, likely appeared because the sample was not stirred during
irradiation. Therefore, if the aliquot for analysis had been removed from the direct path of the
laser (e.g., t = 1, 3 minutes), more uncaging was detected; if the sample was removed from an
area in the cell not directly in the path of the laser (t = 5, 7 minutes), less uncaging was observed.
]In either case, the measurements are not truly reflective of what would be observed in a
homogenous solution. Even so, it is possible to see from these experiments that higher intensity
light sources cause a more rapid rate of uncaging. The best uncaging is seen with the
transilluminator or Laser B, both over 6 mW at the sample. While the transilluminator appears
to have the best rate of uncaging, it is significant to note that the samples become heated while
sitting on the surface of the transilluminator for more than five minutes. The same heating was
nriot observed with the lasers.
Conclusion
Two methods to synthesize peptides incorporating ortho-nitrophenylethyl caged
phosphoserine have been described: the interassembly approach and the building block approach.
Through these methods scientists can access any caged phosphoserine peptide within the limits
of Fmoc-SPPS. Additionally, several caged phosphopeptides were synthesized for biological
studies, and their quantum yields were measured. The quantum yields were found to be
comparable to those of literature values of other ortho-nitrobenzyl caged compounds with similar
substitutions.
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Experimental
2-0. General Synthetic Procedures
All peptide synthesis reagents were purchased from PerSeptive Biosystems (Applied
Biosystems, Foster City, CA) or Novabiochem (EMD Biosciences, San Diego, CA), and all other
chemicals were purchased from Aldrich (St. Louis, MO). Anhydrous dichloromethane, CH2C12,
was distilled from calcium hydride, and anhydrous tetrahydrofuran, THF, was distilled from
sodium/benzophenone. 'H NMR spectra were acquired on a Bruker Avance (DPX) 400 MHz
spectrometer or a Varian Mercury 300 MHz spectrometer. 3C NMR spectra were acquired on a
Varian INOVA 500 MHz spectrometer. 31 p NMR spectra were acquired on a Varian Mercury
300 MHz spectrometer, and all MAS 3 1 p NMR spectra were acquired on a Varian INOVA 500
MHz spectrometer. Chemical shifts are reported in ppm from a standard (tetramethylsilane for
'H, chloroform for 13C, HPO 4 for 31 ), and J values are in hertz. Thin-layer chromatography
(TLC) was carried out on Merck 60 F25 4 250-tm silica gel plates. High-performance liquid
chromatography was performed using a Waters 600E HPLC fitted with a Waters 600 automated
control module and a Waters 2487 dual wavelength absorbance detector recording at 228 and
280 nm. For analytical HPLC a Beckman Ultrasphere C,8, 5 pm, 4.6 x 150 mm reverse-phase
column was used. For preparative separations a YMC-pack, C,8, 250 x 20 mm reversed phase
column was used. The standard gradient for analytical and preparatory HPLC was 93:7 to 0:100
over 35 minutes (water:acetonitrile, 0.1% TFA). Electrospray Ionization Mass Spectrometry
(ESI-MS) was performed on a PerSeptive Biosystems Mariner ™ Biospectrometry Workstation
(Turbo Ion Source). "cp" denotes "caged phospho-."
General Peptide Synthesis Procedures. Peptides were prepared by standard N -
fluorenylmethoxycarbonyl solid phase peptide synthesis (Fmoc-SPPS) on [5-(4-Fmoc-
aminomethyl-3,5-dimethoxyphenoxy)valeric acid]-polyethyleneglycol-polystyrene (Fmoc-
peptide amide linker-PEG-PS or Fmoc-PAL-PEG-PS) resin. For example, 1.00 g (200 [tmol)
Fmoc-PAL-PEG-PS (0.2 mmole/g loading; 1 % DVB) was allowed to swell for five minutes with
5 mL CH2C]2 followed by five minutes with 5 mL N,N-dimethylformamide (DMF) in a 100 mL
peptide synthesis reaction vessel. The resin was deprotected with 3 x 5 mL of 20% piperidine in
DMF (five minutes each), then rinsed 5 x 5 mL DMF (one minute each).
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In each coupling step, 2 equivalents (400 [tmol) Fmoc-protected amino acid and 2
equivalents (400 [tmol) benzotriazole- 1 -yl-oxy-tris-pyrrolidino-phosphonium
hexafluorophosphate (PyBOP) dissolved in 5.0 mL DMF were added to the resin, and the
coupling was initiated by addition of 4 equivalents (800 tmol) N,N-diisopropylethylamine
(DIPEA). Each coupling was allowed to run at room temperature for at least one hour. The
resin was then rinsed 2 x 5 mL DMF (one minute each) followed by 2 x 5 mL CH2C12 (one
minute each). After each coupling reaction, a few beads of resin were tested with trinitrobenzene
sulfonic acid (TNBS) to check for free amines. Upon a negative test, the amino acid was
deprotected as above for chain elongation.
Peptides were cleaved with 90% trifluoroacetic acid (TFA), 5% CH2Cl2, 2.5% water, and
2.5% triisopropylsilane (TIS), then triturated in ice-cold diethyl ether, unless otherwise noted,
and purified by HPLC. Concentrations of the purified stock solutions were determined by
quantitative amino acid analysis of hydrolyzed peptides (2 hours at 145°C with 6 N HCl and
phenol), or by UV absorption of the nitrophenyl group (max at A259 = 5700 M-'cm-' in MeOH).
2-1. Interassembly Approach
.- (2-nitrophenyl)ethanol (NPE-OH), 2. To 2'-nitroacetophenone (1.0 g, 6.1 mmol) in 14.4 mL of
methanol:dioxane (3:2 by volume) sodium borohydride (690 mg, 18.2 mmol) was added and
stirred in a cool water bath, 0 °C, for 20 minutes. The mixture was allowed to stir for 2.5 hours
longer at room temperature (progress monitored by TLC in chloroform, CHC13, and detected by
IJV). The reaction was quenched with 50 mL of water, and then stirred at room temperature for
30 minutes. The mixture was extracted into CHCl3 (3 x 30 mL), dried over sodium sulfate
(Na2 SO4 ) and concentrated under reduced pressure. The alcohol was dried in vacuo overnight to
give a yellow oil, 990.9 mg (97.9%): H NMR (400 MHz, CDCl 3) ppm: 7.9 (d, J= 8.0 Hz, 1
H), 7.9 (d, J= 8.0 Hz, 1 H), 7.7 (t, J= 7.2 Hz, 1 H), 7.4 (t, J= 7.6 Hz, 1 H), 5.4 (q, J= 6.4 Hz, 12.4
H[z, 1 H), 2.4 (s, 1H), 1.6 (d, J= 6.4 Hz, 3H). 13C NMR (125.8 MHz, CDCl 3 ) 6 ppm: 148.1,
141.5, 134.1, 128.5, 128.0, 124.7, 65.9, 24.7. See spectra 2.1 and 2.2.
O-l -(2-nitrophenyl)ethyl-O'-/3-cyanoethyl-N,N-diisopropylphosphoramidite, 4. A solution of 2-
cyanoethyl diisopropylchlorophosphoramidite (471 [tL, 2.11 mmol) in 1.7 mL of anhydrous
CH2CI2 was added to a stirring solution of ortho-nitrophenylethyl alcohol (294 mg, 1.76 mmol)
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and freshly distilled triethylamine (589 [tL, 4.23 mmol) in 8.8 mL of anhydrous CH2C12 at room
temperature in the dark. The reaction was monitored by the disappearance of the ortho-
nitrophenylethyl alcohol by TLC in 65:25:4 methanol:chloroform:water. The reaction mixture
was washed with 10% sodium bicarbonate solution (NaHCO 3) (2 x 30 mL). The organic layer
was then dried over Na2SO4 and concentrated under reduced pressure. The product was dried in
vacuo overnight to give a dark yellow oil, 646 mg (quantitative). H NMR (400 MHz, CDC13) 8:
7.9 (m, 2 H), 7.7 (m, 1 H), 7.4 (m, 1 H), 5.6 (m, 1 H), 3.9 (m, 2 H), 3.7 (m, 2 H), 2.5 (m, 2 H),
1.6 (dd, J= 2.4 Hz, 6.8 Hz, 3H), 1.2 (m, 12 H). 31 p NMR (121 MHz, CDCl 3) : 148.2 (d, J= 45.6
Hz). See spectra 2.3 and 2.4.
In general, peptides were synthesized up to the serine to be phosphitylated, which was
coupled with an unprotected hydroxyl side chain. The resin was dried in vacuo overnight and
swollen in 50:50 anhydrous CH2Cl2 :anhydrous THF. The peptide on resin was then coupled with
the phosphoramlidite reagent (5 equivalents) and H-tetrazole (5 equivalents) overnight, and all
fuirther steps were kept in the dark. The reaction was quenched with 10 % NaHCO 3 and the resin
was rinsed with 50:50 CH 2Cl2:THF, then CH 2Cl2. The phosphitylated resin was then oxidized
with meta-chloroperoxybenzoic acid (mCPBA, 2 equivalents) in CH2C 2 for one hour. The
reaction was quenched with 10% NaHCO 3, and the resin was rinsed well with CH 2 C12 . The
subsequent deprotection of the Fmoc-amine concurrently removed the cyanoethyl protection on
the phosphate, and standard Fmoc-SPPS procedures were employed to complete peptide
synthesis. A sample peptide is described below:
cpERK:
Ac-PL-phospho-1-(2-nitrophenyl)ethyl-seryl-PAKLAFQFP-CONH2
Ftnoc-SPAKLAFQFP-(PAL-PEG-PS). Fmoc-SPAKLAFQFP-(PAL-PEG-PS) was synthesized
using standard Fmoc-SPPS as described above. Data for a portion of cleaved resin: Analytical
reversed phase HPLC, tR= 26.2 min. MS (ESI), m/z calculated for C 69H9 lN13 0 14 : 1327.5 (M+H) +
and 664.3 (M+2H) 2+. Found m/z 1326.8 (M+H)+ and 663.9 (M+2H)2 +.
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Fmoc-phosphi-(O-1-(2-nitrophenyl)ethyl-O' -/3-cyanoethyl)seryl-PAKLAFQFP-(PAL-PEG-PS).
The resin-bound decapeptide Fmoc-SPAKLAFQFP-(PAL-PEG-PS) (200 mg resin, 40 [tmol)
was dried overnight in vacuo. A portion of O-1 -(2-nitrophenyl)ethyl-O'-O-cyanoethyl-N,N-
diisopropylphosphoramidite (73.5 mg, 200 ~tmol) was added the resin, and the vessel was
flushed with nitrogen. The resin was swollen in 3.0 mL of 50:50 anhydrous CH2Cl2 :anhydrous
THF for 10 minutes. The system was charged with H-tetrazole (14 mg, 200 [tmol) and flushed
again with nitrogen. The reaction was agitated overnight in the dark, upon which 3.0 mL of 10%
NaHCO3 solution was added to the reaction mixture and allowed to mix for several minutes. The
resin was rinsed with 50:50 CH2C 2:THF (2 x 5 mL), and then further with CH 2C12 (2 x 5 mL).
Fmoc-phospho-(O-] -(2-nitrophenyl)ethyl-O' -3-cyanoethyl)seryl-PAKLAFQFP-(PAL-PEG-PS).
In a peptide synthesis vessel, Fmoc-phosphi-(O-1-(2-nitrophenyl)ethyl-O'-f3-cyanoethyl)seryl-
PAKLAFQFP-(PAL-PEG-PS) (200mg resin, 40 itmol) was swollen in CH 2C12 . The resin was
placed in 3.0 mL of CH 2C12 , and mCPBA (13.8 mg, 80 [tmol) was added to the solution and
allowed to agitate for one hour at room temperature in the dark. The reaction mixture was then
treated with 3.0 mL of 10% NaHCO3 solution for 5 minutes, and the resin was rinsed with
CH2C12 (3 x 5 mI). Reversed phase HPLC revealed one major and one minor peak. The minor
peak (tR = 26.76 min, 26.5%) corresponded to the starting material. The major peak (tR = 28.76
minutes, 73.5%) was the desired C-terminal product. MS (ESI), m/z calculated for
C80H 02Nl5 O19P: 1609.7 (M+H) + and 805.4 (M+2H) 2+ . Found m/z 805.0 (M+2H) 2+ and 816.0
(M+H+Na)2 +.
Ac-PL-phospho-i-(2-nitrophenyl)ethyl-seryl-PAKLAFQFP-CONH 2 . Chain elongation was
carried out by standard Fmoc SPPS in the dark. After the last residue was added, the N-terminus
was acetyl capped with acetic anhydride (37.8 [tL, 400 [tmol) and pyridine (32.3 [tL, 400 [tmol).
Reverse phase HPLC (tR = 24.6 min). MS (ESI) m/z calculated for C 75H 109 N160 20P: 1586.7
(M+H) + and 793.9 (M+2H) 2 +. Found m/z 793.5 (M+2H) 2+, 804.5 (M+H + Na)2+, and 815.5
(M+2Na) 2+.
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Magic Angle Spinning NMR
The progression of the phosphitylation/oxidation reactions were monitored by Magic
Angle Spinning 31p NMR on Aminomethylated Polystyrene HL resin (Novabiochem, 0.85
mmole/g loading). The sequence H2N-cpSer-Pro-Gly-CONH2 was synthesized on a 200 mg
scale as above, and a 10 mg portion of resin was removed at each step for analysis (3 1 p 6 in ppm,
200 MHz):
- Fmoc-Ser-Pro-Gly-(AM-PS): no 31P signal. See spectrum 2.5.
- Fmoc-phosphi-(O- 1 -(2-nitrophenyl)ethyl-O'-f3-cyanoethyl)seryl-Pro-Gly-(AM-PS):
140.25 (d, J = 85.4 Hz). See spectrum 2.6.
- Fmoc-phospho-(O- 1 -(2-nitrophenyl)ethyl-O'--cyanoethyl)seryl-Pro-Gly-(AM-PS):
-1.68 (s). See spectrum 2.7.
- Phospho- 1-(2-nitrophenylethyl)seryl-Pro-Gly-(AM-PS): 0.40 (s). See spectrum 2.8.
2-2. Building Block Approach
N~-Fmoc-hydroxytrityl-L-serine tert-butyl ester, 10. N-Fmoc-hydroxytrityl-L-serine (2.17 g,
'3.80 mmole) was dissolved in 12.6 mL anhydrous CH2Cl2:THF 4:1 by volume. To the stirring
solution was added t-butyl 2,2,2-tricholoracetimidate (2.72 mL, 15.20 mmole). The reaction was
allowed to stir at room temperature overnight under argon. The reaction was then concentrated
under reduced pressure and redissolved in ethyl acetate (EtOAc) (50 mL). The solution was
washed with 10%9 NaHCO3 (2 x 100 mL), and then saturated sodium chloride (brine) (1 x 100
mL). The organic layer was dried over magnesium sulfate (MgSO4), filtered, and concentrated.
The crude product was purified by chromatography on a short plug of basic alumina (1:1
hexanes/EtOAc, Rf = 0.68) to give the product (1.85 g) in 78% yield. H NMR (300 MHz,
CDC13) ppm: 7.75 (d, JHH = 7.5 Hz, 2H), 7.62 (q, JHH = 4.8 Hz, 2H), 7.41-7.19 (m, 19H), 5.83
(JHH = 8.1 Hz, 1H), 4.39 (m, 3H), 4.25 (t, JHH = 6.9 Hz, 1H), 3.47 (s, 2H), 1.44 (s, 9H).. 3C NMR
(125.8 MHz, CDCl3) ppm: 170.3, 156.6, 144.7, 144.6, 144.3, 142.1, 142.0, 129.4, 128.7,
128.5, 128.0, 127.9, 126.0, 127.0, 120.8, 87.1, 83.1, 68.0, 64.8, 55.7, 47.9, 28.8. ESI-MS:
[MNa]+ 648.2708 (obsd), 648.2720 (calcd). See spectra 2.9 and 2.10.
Na-Fmoc-L-serine tert-butyl ester, 11. N-Fmoc-hydroxytrityl-L-serine tert-butyl ester (1.85 g,
2.96 mmole) was dissolved in 70 mL CH2C1I with 1% trifluoroacetic acid (TFA) and 5%
triisopropylsilane. The solution was allowed to stir at room temperature for one hour. The
mixture was diluted with CH2C12, (100 mL), and washed with 10% NaHCO 3 (2 x 100 mL) and
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then brine (1 x 100 mL). The crude mixture was dried over MgSO 4, filtered, and concentrated
under reduced pressure. The crude product was purified by silica gel flash chromatography (1:1
hexanes/EtOAc, Rf = 0.28) to give the product (1.12 g) in 99% yield. H NMR (300 MHz,
CDCl3) b ppm: 7.74 (d, JHH = 7.2 Hz, 2H), 7.59 (d, JHH = 7.2 Hz, 2H), 7.40 (t, JHH = 7.5 Hz, 2H),
7.31 (t, JH = 8.4 Hz, 2H), 5.75 (d, JHH = 6.3 Hz, 1 H), 4.40 (d, JHH = 7.2 Hz, 2H), 4.33 (t, JHH =
3.6 Hz, 1H), 4.22 (t, JHH = 6.9 Hz, 1H), 3.92 (d, JHH = 2.1 Hz, 2H), 2.22 (bs, 1H), 1.48 (s, 9H).
t3C NMR (125.8 MHz, CDCl3 ) b ppm: 170.5, 157.2, 144.6, 144.5, 142.01, 141.99, 128.4, 127.8,
125.9, 120.72, 120.71, 83.5, 67.9, 64.2, 57.4, 47.8, 28.7. ESI-MS [MH]+ 384.1816 (obsd),
384.1805 (calcd). See spectra 2.11 and 2.12.
N%-Fmoc-phosphi-(O-]-(2-nitrophenyl)ethyl-O'-13-cyanoethyl)-L-serine tert-butyl ester, 12. In a
round bottom flask under argon, N~-Fmoc-L-serine tert-butyl ester (930 mg, 2.43 mmole) was
dissolved in 12 rnL anhydrous THF, and left stirring. In a pear-shaped flask under argon, O-l-(2-
nitrophenyl)-ethyl-O'-f3-cyanoethyl-N,N-diisopropylphosphoramidite (1.51 g, 4.12 mmole) and
4,5-dicyanoimidazole (487 mg, 4.12 mmole) were dissolved in 12.3 mL anhydrous THF, and
allowed to stir for several minutes in the dark. The phosphoramidite solution was added into the
stirring serine solution via cannula under positive argon pressure, and allowed to stir at room
temperature in the dark overnight, under inert conditions. The reaction was judged complete by
disappearance of the starting material and appearance of the product by TLC (EtOAc/hexanes, Rf
= 0.43). The crude mixture was concentrated under reduced pressure and redissolved in EtOAc
(100 mL). The solution was washed with 10% NaHCO 3 (2 x 100 mL), and then brine (1 x 100
mL). The crude material was dried over Na2SO4, filtered, concentrated under reduced pressure,
and used immediately in the following reaction.
N('-Fmoc-phospho-(O-]-(2-nitrophenyl)ethyl-O'-f3-cyanoethyl)-L-serine tert-butyl ester, 12. N -
Fmoc-phosphi-(1-nitrophenylethyl-2-cyanoethyl)-L-serine tert-butyl ester (1.58 g, 2.43 mmole)
was dissolved in 97.2 mL CH2C12. meta-Chloroperoxybenzoic acid (837 mg, 4.86 mmole) was
added to the solution and allowed to stir in the dark at room temperature for one hour. The
solution was then washed with 10% NaHCO 3 (2 x 100 mL), and then brine (1 x 100 mL). The
organic layer was dried over MgSO4, filtered, and concentrated under reduced pressure. The
product was purified by silica gel flash chromatography (1:2 hexanes/EtOAc, Rf = 0.23) to give
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the product (1.27 g) in 79% yield over two steps. H NMR (300 MHz, CDC1 3) ppm: 7.94 (m,
1H), 7.73 (d, JMHH = 7.5 Hz, 3H), 7.60 (d, JHH = 5.7 Hz, 3H), 7.38 (m, 5H), 6.14 (m, 1H), 5.79 (m,
1H), 4.42 (m, 4H), 4.23 (m, 4H), 2.65 (m, 2H), 1.72 (m, 3H), 1.47 (m, 9H). 13C NMR (125.8
MHz, CDCl3) b ppm: 168.3, 156.6 (d, Jpc = 4.0 Hz), 147.5, 144.5 (d, Jpc = 4.0 Hz), 141.9 (d, Jpc
= 2.4 Hz), 137.7, 134.7 (m), 129.8, 128.5 (d, Jpc = 2.4 Hz), 128.3, 128.2 (d, JPc = 5.7 Hz),
127.8, 125.9, 125.4 (m), 120.7, 117.1, 84.1 (m), 74.2 (m), 68.7 (m), 68.0 (d, JPc = 12.8 Hz), 63.1
(m), 55.4 (m), 47.7, 28.6 (t, Jpc = 2.3 Hz), 24.9 (dd, Jpc = 5.2 Hz, Jpc = 2.89 Hz), 20.3 (d, Jpc =
7.4 Hz). 3 NMR (121.5 MHz, CDCl 3) ppm: -2.20,-2.31,-2.41. ESI-MS [MNa] 688.2011
(obsd), 688.2031 (calcd). See spectra 2.13, 2.14, and 2.15.
N'-Fmoc-phospho-(O-l-(2-nitrophenyl)ethyl-O'-,f-cyanoethyl)-L-serine, 13. Na-Fmoc-phospho-
(0-1-(2-nitrophenyl)ethyl-O'-1-cyanoethyl)-L-serine tert-butyl ester (500 mg, 751 [imole) was
dissolved in 35.6 mL CH2 Cl 2 at 25 °C in the dark. A 3.75 mL aliquot of triisopropylsilane was
added to the solution, followed by 35.6 mL of TFA. The solution was allowed to stir in the dark
at 25 C for 2 hours. CH2C 2/TFA was removed by evaporation. The mixture was then
redissolved in EtOAc (80 mL), washed with 10% NaHCO 3 to pH 5, and then washed with brine
(1 x 50 mL). The product was purified by silica gel flash chromatography (65:25:4
CHCl 3/MeOH/H,O, Rf = 0.44) to give the final product (293 mg) in 64% yield. H NMR (300
MHz, CDCl 3) ppm: 7.92 (d, JHH = 8.1 Hz, 1H), 7.73 (d, JHH = 7.5 Hz, 3H), 7.64 (m, 3H), 7.38
(m, 5H), 6.15 (m. 1H), 6.00 (m, 1H), 4.58 (m, 8H), 2.67 (m, 2H), 1.73 (m, 3H). 3C NMR (125.8
MHz, CDC13) 6 ppm: 171.1, 156.7, 147.5 (d, Jc = 4.0 Hz), 144.5 (d, J = 21.7 Hz), 142.0, 137.4
(m), 134.8 (m), 129.9 (m), 128.5, 128.3, 127.9 (d, Jpc = 4.0 Hz), 126.0 (m), 125.4 (m), 120.7,
117.3 (dd, Jpc = 9.7 Hz, Jpc = 16.1 Hz), 74.7 (m), 68.6 (m), 68.2 (m), 63.5 (m), 54.8 (d, Jpc = 7.4
Hz), 47.7 (m), 20.2, 14.9 (dd, Jc = 15.0 Hz, JPc = 7.4 Hz). 3 P NMR (121.5 MHz, CDCl 3) 
ppm: -3.09. ESI-MS [MNa]+ 632.1412 (obsd), 632.1405 (calcd). See spectra 2.16, 2.17, and
2.18.
2-3. Peptides for Biological Studies
Characterization of peptides by either the interassembly or the building block approach:
cpCS: Ac-RRGcpSPG-CONH2
Reverse phase HPLC (tR = 20.0 min). MS (ESI) m/z calculated for C34H55N, 4 0 13P: 899.9
(M+H) +. Found nm/z 899.6 (M+H) +. See spectrum 2.19.
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cpERK: Ac-PLcpSPAKLAFQFP-CONH2
Reverse phase HPLC (tR = 26.6 min). MS (ESI) m/z calculated for C 75 Hlo9N1 60 2 0 P:
1585.8 (M+H) + and 793.4 (M+2H)2 +. Found m/z 1586.5 (M+H) +, 793.7 (M+2H) 2+. See
spectrum 2.20.
cpRSLP: Ac-MARRLYRcpSLPAKK-CONH2
Reverse phase HPLC (tR = 21.2 min). MS (ESI)
1861.1 (M+H)+. 621.0 (M+3H)3 +, and 466.0 (M+4H)4 +.
(M+4H)4 +. See spectrum 2.21.
m/z calculated for C80H135 N2 60 21PS:
Found m/z 621.8 (M+3H)3 +, 466.8
cpPAX: Ac-CSSPPLPGALcpSPLYGVPET-CONH2
Reverse phase HPLC (tR = 23.3 min). MS (ESI) m/z calculated for C9 5H144 N210 32 PS:
2156.3 (M+H) + ,and 1101.7 (M+2H+2Na) 2 +. Found m/z 1102.5 (M+2H+2Na) 2+. See spectrum
2.22.
2-4. Quantum Yield Calculations
Samples were irradiated with a UVP UV Transilluminator, 365 nm, 7330 [tW/cm 2 at the
surface, in vessels with a lmm path length. The quantum yield, (P, of each peptide was
determined by comparison to the known (I of caged phosphate as previously reported. 12 An A350
value was measured for each sample at a l mm path length in water, pH 7.1. Below is a sample
calculation for cpERK.
(cpERK = (cp X %ACpERK x A p
%Acp A35 0cpERK
(cpERK = 054 x 16.38% x 0.01911
18.50 % 0.03506
(cpERK = 0.2606
OC)ERK = 0.26
Data Table for caged phosphate (500
Peak Name Retention
Time (minutes)
Inosine (t = 0) 3.36
Caged P (t = 0) 14.91
Inosine (t = 15 s) 3.21
Caged P (t= 15 s) 14.69
PM):
Average Area Average
Normalized Area
0.559 1.000
16.737 29.941
0.686 1.000
16.739 24.401
Average A350 inAverage A350 in
water, pH 7.1
0.01911
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Data Table for cpERK (547 M):
Peak Name Retention Time
(minutes)
Average Area Average
Normalized Area
Average A350 in
water, pH 7.1
Inosine (t = 0) 3.30 0.641 1.000 -
cpERK (t = 0) 30.47 24.664 38.477 0.03506
Inosine (t = 15 s) 3.37 0.713 1.000 ----
cpERK (t = 15 s) 30.58 22.939 32.173 ----
· cpERK = 0.26
Data Table for cpRSLP (266 MM):
Peak Name Retention Average Area Average Average A350 in
Time (minutes) Normalized Area water, pH 7.1
Inosine (t = 0) 2.90 0.5916 1.000 ----
cpRSLP (t =0) 23.99 5.0259 8.495 0.01477
Ilnosine (t = 15 s) 2.98 0.6540 1.000 ----
cpRSLP (t= 15 s) 23.96 4.9348 7.546 ----
,cpRSLP = 0.42
Data Table for cpCS (757 4M):
Peak Name Retention Average Area Average Average A350 in
Time (minutes) Normalized Area water, pH 7.1
lnosine (t = 0) 3.26 0.6310 1.000 ----
cpCS (t = 0) 17.92 47.3558 75.049 0.04952
Inosine (t = 15 s) 3.28 0.6251 1.000 ----
_cpCS (t = 15 s) 17.93 38.3391 61.333 ----
OcpCS = 0.21
cpPAX: quantum yield not measured; peptide was never used in biological studies.
Testing photolysis sources
The sources used in this study were as listed in Table 2.2. In all cases, the sample
consisted of 274 ixM cpERK, 500 tM inosine, and 500 tM DTT. A sample was irradiated for 9
minutes total, and aliquots were removed from each sample at 2 minute increments for HPLC
analysis. The percent loss of caged phosphopeptide was determined as for quantum yield
mneasurements.
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Chapter 3
Revealing a Global Temporal Role for 14-3-3 in Cell Cycle Regulation
Portions of this chapter have been published in Nature Biotechnology as noted in the text.' Dr.
Justine Stehn (Yaffe Lab, M. I. T.) performed cell lysate assays; Dr. Ahnco Nguyen (Yaffe Lab,
M. I. T.) performed Isothermal Calorimetery (ITC) and cell cycle analysis assays.
Introduction
There is considerable interest in studying phosphoserine/threonine-binding domains,
which constitute an expanding collection of modular signaling domains with significant roles in
regulating pathways such as mitosis, cell response to DNA damage, and apoptosis.2 These
domains contain a subset termed 14-3-3 proteins, which have been extensively studied. The
name of the protein family comes from the fraction number of DEAE-cellulose chromatography
and its migration position in starch-gel electrophoresis. Studies have revealed that more than 50
signaling molecules can be regulated by 14-3-3 proteins, and they are thought to play a pivotal
role in the regulation of protein kinase activation, cell cycle control, neural development and
bacterial or viral pathogenesis. 3 The 14-3-3 family comprises dimeric, ac-helical, cup-shaped
molecules present in high abundance in eukaryotic cells. In humans there are seven distinct
isoforms that bind to each other to form homodimers or heterodimers which are biologically
active.' The dimers form a cleft which preferentially binds phosphopeptides or phosphoproteins
containing an RSx[pS/pT]xP or RxOx[pS/pT]xP motif ' (uppercase bold denotes the most
conserved residues, the prefix p denotes phosphoryl-, 0 denotes aromatic or aliphatic residues,
and x represents any amino acid). While the structural basis of 14-3-3 protein interactions with a
target peptide have been elucidated, the physiological effect of the 14-3-3 family in mammalian
cells remained elusive.3
Most 14-3-3 family members display functional redundancy since the residues that line
the binding cleft are highly conserved among all 14-3-3 isoforms.6 The multiplicity of isoforms
present in cells creates functional redundancy in the case that one isoform is knocked out or
down-regulated within the cell. A single isoform knockout would be compensated for with the
other six isoforms, and simultaneously knocking out all seven isoforms is technically daunting, if
not impossible. Therefore, classical genetics approaches to elucidate the global and temporal
roles for 14-3-3 proteins are not suitable for studying this protein family. We aimed to determine
the global and temporal role of 14-3-3 protiens in live cells by effectively knocking out the entire
protein family upon uncaging of a phosphopeptide designed to bind within the 14-3-3 dimer
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cleft. In this case study, the caged phosphopeptide acts as a masked inhibitor of 14-3-3. The
peptide sequence. MARRLYRSLPAKK was designed by structural analysis of the 14-3-3
binding cleft;4 the highlighted serine residue is that which is phosphorylated when bound to 14-
3-3.
At the time of the studies discussed below, 14-3-3 had been implicated in the regulation
of mitosis by association with several proteins known to regulate mitotic entry, including
Cdc25C, Chkl, Weel and Cdk2. 7 8 However, its precise role was unknown. Additionally, it
was thought that S-phase checkpoint arrest after DNA damage did not involve 14-3-3; rather,
Chkl/2-regulated ubiquitin-mediated degradation of Cdc25A was thought to cause the arrest.9' 10
With the caged phosphopeptides, we were able to determine a temporal functional role for the
14-3-3 family at M-phase entry in cells cycling normally and at S-phase checkpoint for cells with
DNA damage.
Results and Discussion
3-1. Design and Synthesis of Peptides for In Vitro Studies
In order to effectively bind all isoforms of 14-3-3 in cell systems, either in vitro or in
vivo, several series of peptides containing the sequence MARRLYRSLPAKK were synthesized.
The first series of N-acetyl capped peptides were synthesized for in vitro binding assays. The
complete sequences are shown in Figure 3.1. Three of the peptides are in different
phosphorylation states: unphosphorylated (Ac-RSLP), phosphorylated (Ac-cpRSLP), or caged
phosphorylated (Ac-cpRSLP). The last peptide, Ac-cpMAQQ, represents a scrambled sequence
that includes a centrally located caged phosphoserine residue but is missing the key binding
residues flanking the phosphoserine such that the uncaged peptide cannot bind 14-3-3. This
peptide was synthesized to serve as an ultimate negative control: the uncaging event and sudden
appearance of phosphopeptide should have no effect on the system under study.
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Figure 3.1. Peptides synthesized for in vitro binding studies of 14-3-3 proteins. Three peptides
represent three phosphorylation states of the target peptide, Ac-RSLP, Ac-pRSLP, and Ac-cpRSLP.
The last peptide represents a mutant sequence for a negative control, Ac-cpMAQQ. The serine of
interest is highlighted in red.
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3-2. In Vitro Binding of Peptides to 14-3-3
The quantum yield of Ac-cpRSLP was successfully determined ( = 0.43, Chapter 2).
Also, the amount of phospho-peptide released under the conditions used for live cell assays was
measured. After 90 seconds of irradiation at = 365nm, approximately 80% of the
phosphopeptide was photoliberated as determined by HPLC analysis (Figure 3.2). Next,
isothermal calorimetry (ITC) and in vitro assays were performed in collaboration with the Yaffe
lab (Department of Biology, M. I. T.) to determine the peptides binding to 14-3-3 proteins.
Isothermal Calorimetery measurements revealed a 35,000-fold increase in the binding affinity of
the phosphopeptide for 14-3-3-3 after uncaging. The binding constant of the caged
phosphopeptide was 900 [tM, and after UV-irradiation, the binding constant was 25 nM (Figure
3.3).
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Figure 3.2. Photochemical cleavage of Ac-cpRSLP peptide.' Ac-cpRSLP was analyzed by HPLC before
or after UV-A irradiation (left or right panel, respectively). Ac-cpRSLP and Ac-pRSLP were confirmed by
mass spectrometry (ESI-MS). Internal marker inosine and dithiothreitol (DTT) are labeled.
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Figure 3.3. ITC demonstrates UV-A induced release of high-affinity 14-3-3 peptide.' Left panel: UV-
A irradiated peptide was serially pulse-injected into a solution of 14-3-3-P. Right panel: Analysis of
the heat trace shows low- and high-affinity 14-3-3 binding peptides with binding constants of 900
FM and 25 nM, respectively (gray squares). Without UV-A-irradiation, only the low-affinity species
is present (black squares).
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Next the peptides were tested to determine the potential to displace endogenous ligands
for 14-3-3 in whole cell lysates. In the first assay, bead immobilized glutathione S-transferase
(GST)-14-3-3-, and ~ were incubated together with the peptide to be tested, and then subjected
to endogenous ligands from U2OS cell lysates (U2OS, osteosarcoma cells). Each peptide,
RSLP, pRSLP, cpRSLP (no UV), cpRSLP (with UV), and a control without peptide was
incubated with the 14-3-3 beads followed by cell lysate. Binding was detected by SDS-PAGE
and Western analysis blot with a mode 2 antibody to probe for phospho-specific binding events
(Figure 3.4a). It appeared that cpRSLP has the activity of pRSLP after UV treatment, and could
compete off the endogenous ligands. Additionally, neither RSLP nor cpRSLP without UV
treatment affected ligand binding to 14-3-3. The second in vitro assay involved the same
competition experiment, but the peptides were first incubated in cell lysate, then added to the
immobilized 14-3-3 and probed for binding (Figure 3.4b). The results were identical to those of
the first assay. These experiments also demonstrated that the proteases present within a cell
would not degrade the caged or uncaged peptide. Western analysis revealed that the peptides
were indeed stable to the components of a cell system.
U20S ysates Peptide
Peplide ± UV Peptide Peptide ± UV
e _ (Caged)
14-3-3-GST J Ca 14-33 GST 
I- Z _ _ _ 0 
ish U2OS lysates - . _ Blot: Mode2 Ab ,:
Blot: Mode2 Ab ' 
.~ i
Figure 3.4. Uncaged but not caged phosphopeptide competes with endogenous cellular proteins for
binding to 14-3-3.:' Left panel: Ac-cpRSLP (Caged) before or after UV-A-irradiation was incubated with
bead-immobilized GST-14-3-3-3 and , then added to U2OS cell lysates. 14-3-3 bound proteins
detected by immunoprecipitation with a polyclonal antibody against the 14-3-3 binding motif. Controls
show proteins bound by GST-14-3-3 beads pre-incubated with Ac-pRSLP (pSer), Ac-RSLP (Ser), with
no peptide, or by beads containing GST alone. TCL denotes total cell lysate. Right panel: Ac-cpRSLP
(Caged) before or after UV-A-irradiation were incubated with U2OS cell lysates for 30 minutes, then
(G3ST-14-3-3- and ~ beads were added and bound proteins detected as in the left panel. Controls are as
described in the left panel.
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3-3. Design and Synthesis of Peptides for Live Cell Assays
In order to introduce the caged phospho-peptides into large living cell populations, a mild
and efficient method of incorporation was desired. Protein Transduction Domains (PTDs) are
cell internalization sequences derived from natural proteins known to translocate biomolecules
across cell membranes via a passive transport mechanism. Therefore, these cell membrane
permeable sequences are able to carry cargo by what has been dubbed a "Trojan horse"
approach." Both an analog of the HIV-TAT protein transduction domain, PTD4, and the single
substitution mutant of the third helix of the Antennapedia homeodomain, 3Ah, are well
characterized in the literature, displaying the ability to carry in various types of cargo.' 2 13 Three
PTDs were analyzed for introducing caged phosphopeptides into cell populations. One, 3Ah, was
most efficient in its relative ease of synthesis and efficient cellular uptake.
The three PTDs tested were: PTD4 2 (GGGYARAAAYQARA-CONH2), and arginine
tryptophan analog of 3Ah (RRWRRWWRRWWRRWRR), and 3Ah3 (RQIKIWFQNRR-Nle-
IKWKK-CONH 2). A FITC (fluorescein-5-isothiocyanate) tag was coupled to the N-terminus of
each internalization sequence. The spectroscopic properties of FITC allowed peptide
visualization without interfering with the caging group (FITC X.b = 494 nm, kem = 519 nm;
nitrophenylethyl Xabs < 365 nm). Due to the difficulty of cleavage and purification of the "all"
arginine and tryptophan analog of 3Ah, persuit of this sequence was discontinued. PTD4 was
successfully synthesized with an N-terminal fluorescein tag. The single substitution mutant 3Ah
(the native Antennapedia homeodomain contains a methionine instead of norleucine) was
synthesized with an N-terminal fluorescein tag in place of the arginine-tryptophan analog. This
sequence was slightly more difficult to purify than PTD4 because the arginine protecting groups
used in Fmoc SPPS required longer cleavage times (see Chapter 2), while the tryptophan
residues favored shorter cleavage times to prevent alkylation on C3 of the indole ring.
Ultimately, carefully timed conditions with high scavenger concentrations afforded the desired
peptide.
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Figure 3.5. FITC-PTD4 and FITC-3Ah peptides in Ratl fibroblasts. Cells at 70% confluence were
incubated with 12.5 FM peptide for 30 minutes, rinsed with phosphate buffered saline, fixed with
methanol, and, imaged. Images are unaltered.
The fluorescein labeled peptides, FITC-PTD4 and FITC-3Ah, were tested for their ability
to enter Ratl fibroblast cells. Cells were approximately 70 % confluent when they were
incubated with either peptide at 12.5 FM in culture media. Cells were rinsed several times before
fixing and imaging. After 30 minutes, FITC-3Ah was internalized by the cells, which was
evidenced by their bright fluorescence, while cells with FITC-PTD4 were rather dim (Figure
3.5). The 3Ah peptide was selected as the internalization sequence for future experiments
because of its ability to permeate cells and its relative synthetic ease.
Initially the PTD was included at the C-terminal end of the target peptide sequence,
cpRSLP, with a Gly-Gly linker. This construct was prepared by standard Fmoc-SPPS; the caged
phosphoserine was installed via the interassembly approach as previously described (Chapter 2)
and the peptide was stored in the dark. During the synthesis of the linear construct, test cleavages
revealed that the cyanoethyl-group on the caged phosphate was still intact, even after successive
rounds of coupling and with 20% piperidine Fmoc-deprotection treatments. Several deprotection
conditions were tested to remove the cyanoethyl-group without causing 3-elimination of the
phosphate group. A limit to the base concentration was essential because too much base caused
phosphate elimination (Figure 3.6b) before the desired cyanoethyl-group removal (Figure 3.6a).
Conditions tested include: higher concentrations of piperidine in N,N-dimethylformamide (DMF)
(25%o, 30%, or 50% piperidine), 20% piperidine in NA-methylpyrrolidinone (NMP, to break up
any potential secondary structure resulting from the internalization sequence), and increasing
concentrations o)f the strong base 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) in dichloromethane
(20%, 25%, or 30% DBU). Unfortunately, all treatments resulted in either -elimination of the
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phosphate or no reaction. Therefore, a new approach was selected in which the cargo peptide
was tethered to 3Ah via a disulfide bond.
a
cyanoethyl- elmination:
leaves caged phosphoserine in
peptide sequenceAN'kA~-\ HB+0X HB+0
b
NO2 0 N
H
- . OH H phosphate A-elimination:
leaves dehydroalanine in
HB+;~~ iNN0 ~ \peptide sequence
HB+ /N'
0 0 '
Figure 3.6. Possible 5-elimination reactions during longer caged phosphopeptide synthesis. a) The
desired elimination of the temporary cyanoethyl- protecting group. b) The undesired elimination of
the entire phosphate group.
With the disulfide construct, it was possible to internalize the target peptides via the PTD;
once in the reducing environment of the cell, the disulfide was reduced, and each peptide would
then act independently within the cell. Towards this end, heterodimerization of cysteine
containing peptides was previously reported.4 A more recent study compared a releasable
disulfide linked internalization-target sequence conjugate to a non-releasable construct. While
the non-releasable construct efficiently internalized the target sequence, the in vivo activity
suffered significantly. In contrast, the disulfide-linked peptide had the ability to be internalized
and was able to affect the target system with high success. 5 The loss of function in the non-
releasable construct may have stemmed from secondary structure interactions of the extended
peptide. An alternative structural state caused by interactions with the PTD may prevent a given
peptide from reaching the intended target.
Fluorescein tagged RSLP target sequences were linked to the 3Ah sequence by a
disulfide bond as in Scheme 3.1. Fluorescein labeled-peptides were synthesized using standard
Fmoc-SPPS; caged phosphopeptides were synthesized using the building block approach
described in Chapter 2. The 3Ah peptide 15 was synthesized by standard Fmoc-SPPS, and
activated with 2,2'-dithiobis(5-nitropyridine) to afford 16. Next, 16 was coupled with the
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Scheme 3.1 Synthesis of FRSLP-SS-3Ah peptide series: peptides for cellular uptake.
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fluorescein-tagged peptide 14 in relatively low pH buffer (pH 5.1) under inert atmosphere to
generate the disulfide linked construct 17. The control constructs with a free serine (18) or the
mutant sequence (19) were also synthesized in this manner. Several coupling conditions were
tested in order to synthesize the desired mixed disulfide and avoid oxidation to symmetric
disulfides. Low pH (3 to 4) did not allow for proper coupling, most likely due to the large
number of basic residues on both peptides. The positively charged species at low pH would
repel each other and would not be able to come into close enough contact to react and form the
heterodimer. Alternatively, if the pH was raised (6 to 8) to encourage the peptide association,
base catalyzed oxidation and homodimerization became a significant problem. Unfortunately, the
mutant peptide was particularly difficult to couple to the antennapedia (3Ah) portion. Figure 3.7
demonstrates the rapid decomposition of the desired compound (19) to deactivated 3Ah (15) and
homodimerized scrambled peptide. This phenomenon was not found to be pH dependent, but
rather time dependent; as the reaction progressed at various pH values (4 to 6) homodimer
formed at similar rates. Ultimately, sufficient peptide was synthesized for biological
experiments.
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Figure 3.7. Decomposition of FMAQQ-SS-3Ah, 19. Left panel: Schematic of decomposition process.
Right panel: Analytical HPLC trace of reaction mixture at initial reaction time (t = 0). Products were
assigned by ESI-MS and labeled appropriately.
The constructs were tested for their ability to be internalized into Rat 1 fibroblast cells,
and compared to positive and negative controls as shown in Figure 3.8. All constructs tethered
to 3Ah were taken up by cells significantly better than the corresponding non-3Ah analogs. It is
interesting to note the background fluorescence observed in the FITC tagged RSLP peptides not
conjugated to the 3Ah sequence. This low level of background may be due to the positively
charged nature of the RSLP sequence (5 of the 13 residues are basic). A common feature of the
natural protein transduction sequences is the prevalence of arginine and lysine residues. For
further discussion of this phenomenon, please see reference 16.
FITC-3Ah FRSLP-SS-3Ah FoRSLP-SS-3Ah FcpRSLP-SS-3Ah
no peptide FRSLP FpRSLP FcpRSLP
Figure 3.8. FRSLP and FRSLP-SS-3Ah peptide series in Ratl fibroblasts Cells were grown to 70 %
confluence and then incubated with 12.5 tM peptide for 30 minutes at 37°C. Cells were rinsed with
phosphate buffered saline, fixed with methanol, and imaged. Images are unaltered.
58
( C2
0.1
Product:
FTTC-cp
Ac-cys
Ac-
0
........ 
I.,
u.-1 
n - n x a on ha Qrz ho In
_I u
With successful uptake into Rat 1 fibroblasts, peptides were introduced into U2OS cells
(which are the preferred cells for the analysis of 14-3-3 function) and a series of control
experiments were performed to ensure neither the free serine analog nor UV-A irradiation of the
cells would cause any aberrant effects in the cells. U20S cells were synchronized with
mimosine (a plant nonprotein amino acid known to cause G1/S phase arrest)l7 and released from
the block. One set of cells was left untreated (No UV), one set of cells was UV-A irradiated
(+UV), and a third set of cells was treated with the free serine construct 18 and UV-A irradiated.
All cells were monitored for their cell cycle progression by Fluorescence-Activated Cell Sorting
(FACS) analysis (Figure 3.9). No difference was observed in the progression through the cell
cycle with the various conditions tested.
3-4. Defining a Global Temporal Role for 14-3-3*
At the time of the experiments, the 14-3-3 family of proteins had been implicated in
regulation of mitotic-phase entry by association with various proteins known to regulate this
portion of the cell cycle. However, 14-3-3 interacted with proteins that either had positive or
negative effects on G2/M phase progression." ' 8 Therefore, in order to elucidate the role of 14-3-
3, caged phospho)peptides were used to effectively knock out the 14-3-3 family in synchronized
cells so that downstream cell cycle effects could be monitored. U2OS cells were synchronized
with mimosine in G1/S, released, and treated with either peptide 17 or 18 at a time point
corresponding to late S phase or very early G2 (t = 9 h after mimosine release). After 30
minutes, cells were exposed to UV-A irradiation ( = 365 nm) for 90 seconds and analyzed at
subsequent time points by both FACS analysis and immunohistochemistry with an antibody to
the known mitotic marker phospho-histone H3 (Figure 3.10).
* A significant portion of this section is taken from reference 1, which was originally written by
Professor Michael Yaffe (M. I. T. Department of Biology).
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Figure 3.9. UV-A irradiation of cells in the absence or presence of serine-containing control peptides
does not affect cell cycle progression.' U2OS cells were synchronized with mimosine. The cells were
released, and either left untreated, UV-A-irradiated or UV-A irradiated 30 minutes after addition of the
serine control peptide 18. At various time points cells were analyzed by FACS. No difference was
observed under any of the three conditions for progression through the cell cycle.
Control experiments demonstrated that UV-A irradiation 9 h after mimosine release does
not disturb subsequent cell cycle progression (Figure 3.10 a). Next, synchronized cells in the
absence or presence of the caged phosphopeptide 17 were UV-A irradiated and their cell cycle
progression monitored. As seen in Figure 3.10b and c, the population treated with 17
demonstrated three key features due to the loss of 14-3-3 function. First, there was a significant
amount of cell death associated with peptide treated cells 5 h after 14-3-3 disruption (59 % live
cells versus 80 % live cells in the control population). Second, at this same time point, many of
the live cells displayed an accelerated and intense phospho-histone H3 staining relative to the
control (Figure 3. 10d). This suggests that disruption of 14-3-3 at the S/G2 boundary leads to
uncontrolled premature entry into M phase accompanied by mitotic catastrophe. Finally, there
was a significant reduction in the stable G1 cell population and an associated increase in the
G2/M population by 17 hours post-mimosine release in the peptide treated cells versus the
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Figure 3.10. Coordinated, synchronous loss of 14-3-3 function results in aberrant cell cycle progression
and G1 release.' a) U2OS cells were synchronized with mimosine and released; 9 h after release one
population of cells was UV-A irradiated and the control population left untreated. Cells were collected
for FACS analysis of DNA content as a measure of cell cycle progression. b, c) The same passage of
cells from a were synchronized with mimosine and released. At 9 h post-release, cells in c were treated
with caged phosphopeptide 17; at 9.5 h both populations of cells were UV-A irradiated. Cells were
analyzed by FACS for cell cycle progression. d) Cells from b and c were fixed and stained with an
antibody that recognizes phospho-histone H3.
control sample. These results serve as evidence that 14-3-3 proteins normally regulate the onset
and timing of mitosis in cycling cells as well as play a critical role in maintaining stable
interphase arrest in non-cycling cells. Most notably, synchronization of the cells followed by
controlled uncaging of the inhibitor peptide allowed the elucidation of the 14-3-3 protein family
role in real time.
Next, the caged phosphopeptide was used to examine the function of 14-3-3 in S phase
checkpoint function in response to DNA damage. S phase arrest after DNA damage results from
Chkl/2-regulated ubiquitin-mediated degradation of CdC25A, a process that was not thought to
involve 14-3-3 binding.9" 0 In order to test if 14-3-3 proteins are necessary for S phase checkpoint
fuinction, U2OS cells were synchronized, released, and a subset was incubated with the peptide
17 during mid-S phase (6.5 hours post release). Cells were then exposed to UV-A and UV-B
61
tnlh
I
LI-v.
i;
IL
f
.s;
a:
I
0)
Z
Q
0)_~
a _R aver
"!
r - -_ _R ONYX _ 1^ to Ye *#v1 -newt And or- - /lVl
- t=2Ah t = 0 h t=14h t=17h
I
, 1W
.%^~~ ~t=6h t= 16h t = 26h
(I) Control
2N 4N 2N 4N 2N 4N
t= h
2N 4N
(111) +mut caged
peptie
+UV-AB
2N 4N 2N 4N 2N 4N
(Iv) +wt caged
peptide
+UV-A,B
c- 2N 4N
DNA content -
h r Histone H3-P
FITC DAPI Annexin-V
+mut caged
peptide
+UV-A.B
+wt caged
peptide T
+UV-A.B v
* - ' - * C
Ml
FSC
Figure 3.11. Coordinated, synchronous loss of 14-3-3 function results in dysfunctional, DNA-damage
induced S phase cell cycle checkpoint.' a) U2OS cells were synchronized with mimosine and split into
four separate conditions: i) control untreated, nonirradiated cells, ii) cells exposed to UV-A/B
irradiation 7 h after release, iii) cells pre-incubated with 19 before UV-A/B irradiation, and iv) cells
treated with 17 before UV-A/B irradiation. Cell cycle progression was analyzed by FACS. The sub-
G1 population lies to the left of the dashed red line in the lower right panel in iv. b) Cells treated with
mutant (19) or wild-type (17) peptide from panels iii or iv in a were analyzed for programmed cell
death 9 h post irradiation. 40 to 50 % of the 17 treated cells stained positively with PE-conjugated
annexin-V. c) Cells from iii and iv that survived 19 h post irradiation were examined for cell size by
iFACS and for histone H3-phosphorylation.
irradiation ( = 365 nm and 302 nm, respectively) for 90 seconds to simultaneously uncage 17
and induce DNA damage.8 The control peptide 19 was tested for any effect on S phase
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checkpoint function under identical conditions. Peptide 19 corresponds to Ac-cpMAQQ (Figure
3.1) in which the critical residues necessary for 14-3-3 binding had been mutated. All cell
populations were analyzed by FACS at different time points after mimosine release (Figure
3.1 a). Non-irradiated control cells progressed through the normal cell cycle while irradiated
control cells initiated and maintained S phase arrest throughout the ensuing 19 hours (Figure
3.1 la, panels i and ii). Cells that were pretreated with the mutant control peptide 19 displayed
the same S phase arrest as irradiated control cells (Figure 3.1 a, panel iii). However, cells that
were pretreated with peptide 17 (wild type or wt) were unable to sustain S phase arrest (Figure
3.11 a, panel iv), resulting in 40 to 50 % early apoptotic death by 16 h post release as revealed by
annexin-V staining (Figure 3.1 lb). Additionally, a sub-Gl population was visualized by
propidium iodine staining after 26 hours post release (Figure 3.1 l1a, panel iv). A sub-GI
population by FACS analysis denotes cells undergoing apoptosis; they will have lost some of
their DNA due to DNA fragmentation in later apoptosis. By 26 hours, the remaining surviving
cells were smaller (note the shift in the moment of forward and side-scattering ellipse in Figure
3.1 l1c), and displayed prominent phospho-histone H3 staining (Figure 3.1 1 c), suggesting that
these cells were undergoing mitotic catastrophe. The global disruption of 14-3-3 resulted in a
loss of S phase checkpoint function after UV-B irradiation, and this observation was unexpected
since S phase checkpoint function had been thought to be mediated by Chk-1/2 regulated
degradation of Cdc25A. However, with the global temporal role for 14-3-3 observed in these
experiments, it may be that 14-3-3 negatively regulates Cdc25A. Further supporting these
observations, it was recently found that Cdc25A binds 14-3-3 after Chkl activation.9 Once
again, it is noteworthy that the technology and availability of caged phosphopeptides allowed the
real time information that merits future investigation in 14-3-3 function.
Conclusion
Caged phosphopeptides were applied to 14-3-3 family protein binding experiments. A
phosphopeptide sequence was designed to bind to active 14-3-3 dimers, and the corresponding
caged phosphopeptide was synthesized. In vitro, the caged phosphopeptide could not bind 14-3-
3; however, upon uncaging by UV-A irradiation the released peptide bound the target protein as
well as the native phosphopeptide. Further, a series of peptide constructs was synthesized for
studying the function of the 14-3-3 family of proteins in large cell populations. The disulfide
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linkage between the target peptide and the PTD 3Ah was reduced within the cellular
environment allowing each peptide to act independently of each other. Experiments that
incorporated these peptides into synchronized cells determined two global temporal roles for the
14-3-3 protein family in cell cycle progression: 14-3-3 is necessary for G2/M phase progression
and DNA-damage induced S phase checkpoint function. The technology integrated within the
caged phosphopeptides afforded the observations that led to these conclusions. Cells could be
synchronized and then the phosphopeptide released with temporal control; the phosphopeptide
binds extremely tightly in the 14-3-3 binding cleft, essentially knocking out all isoforms of 14-3-
3. It was only with this temporal control that the effects of simultaneously binding all isoforms
of 14-3-3 within a cycling cell population could be observed.
Experimental
3-0. General Synthetic Procedures
All peptides were synthesized using standard Fmoc-SPPS as described in Chapter 2,
unless otherwise noted. All caged phosphopeptides were synthesized via one of the methods
described in Chapter 2. Additional chemical reagents were purchased from Aldrich;
Fluorescein-5-isothiocyanate, isomer I (FITC) was purchased from Molecular Probes, Inc.
(Eugene, OR).
3-1. Design and Synthesis of Peptides for In Vitro Studies
Ac-RSLP.: Ac-MARRLYRSLPAKK-CONH 2
Reverse phase HPLC (tR = 20.9 min). MS (ESI) m/z calculated for C 72 H127 N 25 O,16 5:
1632.0 (M+H) + and 408.8 (M+4H)4 +. Found m/z 408.6 (M+4H)4 +.
Ac-pRSLP: Ac-MARRLYRpSLPAKK-CONH2
Reverse phase HPLC (tR = 20.3 min). MS (ESI) m/z calculated for C 72 H128N25 0 1 9PS:
1711.0 (M+H) +, 571.0 (M+3H)3 +, and 428.5 (M+4H)4 +. Found m/z 572.3 (M+3H) 3+, 429.2
(M+4H) 4 +.
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Ac-cpRSLP: Ac-MARRLYRcpSLPAKK-CONH2
Reverse phase HPLC (tR = 21.2 min). MS (ESI) m/z calculated for C80H135 N2 60 21PS:
1862.1 (M+H) +, 621.0 (M+3H)3 +, and 466.0 (M+4H) 4+. Found m/z 621.8 (M+3H) 3 +, 466.8
(M+4H) 4 +.
Ac-cpMAQQ: Ac-MAQQLYAcpSLAAKK-CONH2
Reverse phase HPLC (tR = 25.6 min). MS (ESI) m/z calculated for C 73Hl 8N19 023 PS:
1693.9 (M+H) +. Found 1693.6 (M+H) +, 846.8 (M+2H) 2+.
3-2. In Vitro Binding of Peptides to 14-3-3
Biological assays were performed as developed, optimized, and described in Reference 1.
All peptides were dissolved in dH2O, pH 7.1, with 5 mM DTT final concentration. Stock
concentrations of Ac-RSLP and Ac-pRSLP were determined by quantitative amino acid analysis.
Stock concentrations of Ac-cpRSLP and Ac-cpMAQQ were determined by UV absorbance (~max
at A259 = 5700 M'cm - in MeOH).
For binding competition assays in buffer, Ac-cpRSLP was irradiated in a 1 mm path
length vessel with a UVP Transilluminator (365 nm, 7330 [tW/cm 2) for five minutes, and
aliquots were removed and analyzed by reverse phase HPLC to confirm release of the caging
group.
For binding competition assays in total cell lysate, the caged peptide was first mixed with
the cell lysate, and then irradiated in a glass vial for five minutes as above. The mixtures were
then incubated with 14-3-3 /~ GST beads and prepared for the immuno-precipitation assay.
Western blot analysis used a Mode-2 primary antibody specific for the phospho-binding
site of 14-3-3.'
3-3. Design and Synthesis of Peptides for Live Cell Assays
FITC-PTD)4. Fmoc-PTD4 (Fmoc-GGYARAAARQARA-CONH2 ) was synthesized by
standard Fmoc-SPPS as described in Chapter 2. Fmoc-E-aminohexanoic acid (ahx) (28.3 mg, 80
Crmole) was coupled to the peptide (200 mg resin, 40 ptmole) using standard coupling conditions.
Following standard deprotection protocol, fluorescein-5-isothiocyanate (FITC) (31.2 mg, 80
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gmole) in 2.0 mL DMF was added to the resin, and coupling was initiated with DIPEA (27.4 tL,
160 jtmole). The coupling was allowed to run overnight in the dark. The resin was rinsed with
DMF (2 x 5 mL x 1 min) and then with CH 2C1 2 (2 x 5 mL x 1 min). The peptide was cleaved
with 90% TFA, 5% CH 2C12, 2.5% TIS, and 2.5% dH 20 for three hours in the dark. The peptide
was triturated with diethyl ether, allowed to air dry, and purified by reverse phase HPLC (tR =
23.36 min). MS (ESI) m/z calculated for C8lHl 14N 26 021S: 1820.7 (M+H) +, 910.9 (M+2H) 2+, 607.6
(M+3H)3 +, and 455.9 (M+4H)4 *. Found m/z: 910.5 (M+2H) 2+, 607.3 (M+3H) 3+, and 455.7
(M+4H) 4 +.
A stock solution was made in phosphate buffered saline (PBS+: 900 [tM calcium
chloride, 2.67 mM potassium chloride, 1.47 mM potassium phosphate, 500 [tM magnesium
chloride, 138 mM sodium chloride, 8.1 mM sodium phosphate, pH 7.1). The concentration was
determined by UV absorbance (max at A49 = 74,500 Mqcm -1 at pH 9.0) in 50 mM KPO 4 H2
buffer, pH 9.0.
FITC-3Ah. Fmoc-3Ah (Fmoc-RQIKIWFQNRR-Nle-KWKK-CONH2) was synthesized
by standard Fmoc-SPPS as described in Chapter 2. Fmoc-E-ahx (28.3 mg, 80 tmole) was
coupled to the peptide (200 mg resin, 40 ltmole) using standard coupling conditions. Following
standard deprotection protocol, FITC (31.2 mg, 80 [tmole) in 2.0 mL DMF was added to the
resin, and the coupling was initiated with DIPEA (27.4 [tL, 160 Rmole). The coupling was
allowed to run overnight in the dark. The resin was rinsed with DMF (2 x 5 mL x 1 min) and
then with CH 2 Cl2 (2 x 5 mL x 1 min). The peptide was cleaved with 82% TFA, 8.5%
ethanedithiol (EDT), 8.0% TIS, and 1.5% dH2O, shaking for 90 minutes in the dark, and then
with fresh solution for an additional 30 minutes. The peptide was triturated with diethyl ether,
allowed to air dry, and purified by reverse phase HPLC (tR = 24.3 min). MS (ESI) m/z calculated
for C 132H 193 N37 025S: 2731.3 (M+H) +. Found m/z: 456.1 (M+6H)6 +, 547.1 (M+5H) 5 +, and 683.6
(M+4H) 4 +.
A stock solution was made in PBS+ and the concentration was determined by UV
absorbance as for FITC-PTD4.
Internalization data. Rat 1 fibroblasts were cultured in Dubelco's Modified Eagle
Medium (DMEM) supplemented with 10% Fetal Bovine Serum (FBS) at 37°C and 5% CO2.
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Cells were seeded onto 18 mm square cover slips and grown until 70% confluent. Cells were
incubated with 12.5 tM final concentration of fluorescein labeled peptide at 37°C, 5% CO2 for
15 minutes, 30 minutes, 1 hour, or 4 hours. Cells were rinsed with PBS+ (3 x 1 min) and fixed
with ice-cold methanol for five minutes. The cover slips were mounted onto glass microscope
slides with 50:50 (v/v) glycerol/water and allowed to dry overnight, dark, room temperature.
Once dry, the cover slips were sealed. Slides were viewed under a fluorescence microscope
through a fluorescein filter with a 100 W Mercury lamp. Images were captured with a CCD
camera using SPOT software and Adobe Photoshop 5.5. No modifications were made to the
images.
General synthesis of disulfide linked peptides. Ac-cys(pys)-3Ah, 16, was synthesized as
described below. FITC-cys-Peptides were synthesized using standard Fmoc-SPPS as described
in Chapter 2; those containing a caged phosphoserine were synthesized using the building block
method described in Chapter 2. Coupling was performed using either Method A or Method B:
Method A: Individual peptides were dissolved in a minimal amount of 1M ammonium acetate
(NH4OAc) buffer, pH 5.1, degassed by bubbling with argon. Peptide stocks were quantified by
1JV absorbance (10 to 15 mM), and stored at -80 °C. One equivalent of each peptide was added
in a reaction vessel flushed with argon, and allowed to agitate for three hours.
Method B: Each lyophilized peptide was added to a reaction vessel in an approximately 1:1
ratio, and the vessel flushed with argon. Degassed 1M NH 4OAc buffer, pH 5.1 was added to the
dry peptides to approximately 10 mM, and the mixture was allowed to agitate for three hours.
For either method, the reaction mixture was quenched with 0.1% TFA in dH20 (to double
the reaction volume), and then extracted several times with EtOAc. The aqueous layer
containing the desired peptide construct was purified by reverse phase HPLC. Peptides were
characterized by reverse phase HPLC and MS (ESI).
Ac-cys(pys)3Ah, 16. Ac-cys-3Ah (15, Ac-CRQIKIWFQNRR-Nle-KWKK-CONH 2) was
synthesized using standard Fmoc-SPPS conditions as described in Chapter 2. 2,2'-dithiobis(5-
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nitropyridine) (39 mg, 125 ptmole) was dissolved in 3:1 AcOH/H 20 (5 mL) to make a 25 mM
solution. 4 mL of solution (100 tmole) was added to lyophilized Ac-cys-3Ah (20 Rmole), and
allowed to mix vigorously for 5 hours. The solvent was removed in vacuo, and the residue
dissolved in 10 mL of 1:1 EtOAc/dH 2O. The aqueous layer was extracted with EtOAc (3 x 5
mL), and then purified by reverse phase HPLC (tR = 21.6 min). MS (ESI) m/z calculated for
Clls5H 18 0N 38 0 23 S2 : 2527.1 (M+H) +, 506.2 (M+5H)5 +, 632.5 (M+4H)4 + . Found: 506.4 (M+5H)5 + and
632.7 (M+4H)4 +.
F-cys-RSLP. FITC-CMARRLYRSLPAKK-CONH2. Analytical reversed phase HPLC (tR = 22.0
min). MS (ESI) m/z calculated for Clo0H152 N280 2 2S3 : 2194.6 (M+H) +, 439.7 (M+5H) 5 +, 549.4
(M+4H)4 +, 732.2 (M+3H)3 +. Found 439.9 (M+5H)5+, 549.6 (M+4H)4+, 732.4 (M+3H)3 +.
F-cys-pRSLP. FITC-CMARRLYRpSLPAKK-CONH2. Analytical reversed phase HPLC (tR =
17.9 min). MS (ESI) m/z calculated for Co10 0H 153 N280 25S3P: 2274.7 (M+H) +, 455.7 (M+5H)5 +,
569.4 (M+4H)4 +, 758.9 (M+3H)3 +. Found 455.8 (M+5H)5+, 569.6 (M+4H)4 +, 759.1 (M+3H)3 +.
F-cys-cpRSLP, 14. FITC-CMARRLYRcpSLPAKK-CONH2. Analytical reversed phase HPLC
(tR = 20.6 min). MS (ESI) m/z calculated for Clo08H160N2 9 027S3P: 2423.7 (M+H) +, 485.5 (M+5H) 5+,
606.7 (M+4H)4 +. Found 485.6 (M+5H)5 +, 606.7 (M+4H)4 +.
F-cvs-cpMAQQ. FITC-CMAQQLYcpSLAAKK-CONH2. Analytical reversed phase HPLC (tR =
27.7, 28.0 min, diastereomers). MS (ESI) m/z calculated for CIolH 144N 2 20 29PS 3 : 2256.6 (M+H) +,
752.9 (M+3H)2 +, 1128.8 (M+2H)2+ . Found 753.0 (M+3H)2+, 1129.0 (M+2H)2 +.
FRSLP-SS-3Ah, 18. (FITC-CMARRLYRSLPAKK-CONH2)-S-S-(Ac-CRQIKIWFQNRR-Nle-
KWKK-CONH 2). Analytical reversed phase HPLC (tR = 23.6 min). MS (ESI) m/z calculated for
C 2 1 0H328 N640 43 S4: 4565.5 (M+H) +, 653.1 (M+7H)7 +, 761.8 (M+6H)6 +, 913.9 (M+5H)5 +. Found
653.2 (M+7H) 7+, 761.9 (M+6H)6 +, 913.9 (M+5H) 5+.
FpRSLP-SS-3Ah. (FITC-CMARRLYRpSLPAKK-CONH2)-S-S-(Ac-CRQIKIWFQNRR-Nle-
KWKK-CONH 2 ). Analytical reversed phase HPLC (tR = 23.6 min). MS (ESI) m/z calculated for
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C210 H32 9N640 46 PS 4 : 4645.5 (M+H) +, 664.5 (M+7H) 7+, 775.1 (M+6H)6 +, 929.9 (M+5H)5 +. Found
664.7 (M+7H)7 -, 775.4 (M+6H)6 +, 930.1 (M+5H)s +.
FcpRSLP-SS-3Ah, 17. (FITC-CMARRLYRcpSLPAKK-CONH2)-S-S-(Ac-CRQIKIWFQNRR-
Nle-KWKK-CONH2). Analytical reversed phase HPLC (tR = 24.1 min). MS (ESI) m/z calculated
for C 218H 336 N65 () 4 8PS4: 4794.7 (M+H) +, 685.8 (M+7H) 7 +, 800.0 (M+6H) 6 +, 959.7 (M+5H) 5 +,
1199.4 (M+4H) 4+. Found 693.2 (M+ 2Na +7H)7+, 808.6 (M+ 2Na +6H) 6 + , 969.9 (M+ Na+ 5H)5 +,
and 1212.4 (M +2Na +4H)4 + .
FcpMAQQ-SS-3Ah, 19. (FITC-CMAQQLYAcpSLAAKK-CONH2)-S-S-(Ac-
CRQIKIWFQNRR-Nle-KWKK-CONH2). Analytical reversed phase HPLC (tR = 24.3 min). MS
(ESI) m/z calculated for C 211H32 0N5 80 5 0PS: 4628.4 (M+H) +, 926.5 (M+5H) 5+, 772.2 (M+6H)6 +.
Found 926.3 (M+5H)5 +, 771.9 (M+6H) 6 +.
3-4. Defining a Global Temporal role for 14-3-3
Experiments were performed as described in Reference 1.
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Chapter 4
Synthesis of Full-length Caged Phosphoproteins
Portions of this chapter have been published in the Journal of the American Chemical Society as
noted in the text' (Copyright © 2005 American Chemical Society). M. E. Vazqu6z (Imperiali
Lab, M. I. T.) synthesized 4PO-cpTyr-OCH2CN; E. James Petersson (Dougherty Lab, CalTech)
performed in vitro suppression reactions with nAChR.
Introduction
The majority of kinase substrates are functional as full-length proteins; therefore, a
generally applicable method for the synthesis of site-directed caged phosphoproteins is desirable.
The technology to incorporate caged phospho-amino acids into full-length protein is described in
this chapter.' This method takes advantage of the nonsense codon suppression methodology, an
overview of which is depicted in Figure 4.1.2 Briefly, the gene of interest is mutated at the site of
unnatural amino acid incorporation to one of the "blank" stop (or nonsense) codons in the
genetic code, often the amber codon TAG. An orthogonal suppressor tRNA with the
corresponding anti-codon to the amber codon is ligated to a dinucleotide that has been
chemically acylated with the desired non-natural amino acid. When the mRNA of the mutated
gene is placed in a translation system with the designed tRNA, the ribosomal machinery
incorporates the unnatural amino acid at the amber codon position, thus suppressing the nonsense
codon.
AGA
oligonucletide-
directed
mutagenesis 
3C /nnAA
pdCpA(cpSer)
T4 RNA igase
/
4)-W .
UAGI
mRNA
AUC
Figure 4.1. Overview of the nonsense codon suppression method. Oligonucleotide-directed
mutagenesis of the gene converts the target amino acid codon to the amber stop codon. A
corresponding tRNA, with the matching anti-codon is ligated to a chemically acylated dinucleotide
containing the non-natural amino acid. When the mRNA of the mutated gene and the tRNA are
combined in a translation system, the non-natural amino acid is incorporated at the amber stop codon
position, thus suppressing the nonsense codon. (nnAA= non-natural amino acid)
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A novel phosphitylation reagent was developed in order to synthesize the appropriately
protected amino acid derivatives for the chemical acylation of the designated suppressor tRNA.
Suppression experiments were performed in two proteins: at position 122 of nicotine
acetylcholine receptor -subunit (nAChR-ct) and at position 153 of murine vasodilator
stimulated phosphoprotein (mVASP). All three commonly phosphorylated residues (serine,
threonine, and tyrosine) were successfully incorporated as their caged analogues in the test
protein nAChR.-cta. The incorporation of caged phosphoserine was successful in the phospho-
regulated protein mVASP (for further discussion, see Chapter 5). The generally applicable
method for synthesizing full-length caged phosphoproteins will broaden the field of study
opened by the successful caged phosphopeptide methodology.
Results and Discussion
4-1. Chemrnical Synthesis
In general, the chemical acylation of the tRNA is accomplished by coupling the unnatural
amino acid to a dinucleotide that corresponds the 3'-end of the suppressor tRNA. This acylated
dinucleotide is then biochemically ligated to the suppressor tRNA in which the two 3'-
nucleotides are absent (see below, section 4-2). There are several key features of the protecting
groups on a non-natural amino acid for coupling to the 3'-dinucleotide of the suppressor tRNA.
The amine-protecting group must be one that is removed under mild conditions such that the
deprotection can be performed on the intact tRNA immediately prior to suppression translation
reactions.3 The most common protecting group is the caging group 6-nitroveratryloxy carbamate
(NVOC)2 ' 4 which is removed with UV-A irradiation (Figure 4.2a). Because the side-chain for the
target amino acid is light-sensitive, the 4-pentenoyl amide was used. This group is removed with
iodine in water at room temperature (Figure 4.2b).5 6 The amino acid activation implements a
cyanomethyl ester, which has been shown in the literature to selectively mono-acylate the
dinucleotide at the 2'- or 3'-hydroxyl groups, and to not acylate the aniline amines of the
nucleotide bases.4
a NO2, 0 R b 0 RoN OCN b NC
H o H
MeO
)Me
Figure 4.2. Amino acids activated by cyanomethyl ester for coupling to the dinucleotide. a) NVOC-
protected amine. b) 4-pentenoyl protected amine.
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Scheme 4.1 -elimination of caged phosphate with transient cyanoethyl protection.
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Several attempts were made to synthesize the appropriate caged phosphoserine and
threonine analogs via the phosphoramidite 4 (Chapter 2). Unfortunately, the 4-pentenoyl amide
and cyanomethyl ester of a caged phosphoserine with the transient 3-cyanoethyl protecting group
undergoes -elinination of the phosphate during basic deprotection (Scheme 4.1). Therefore, a
non-base labile transient phosphate protecting group was required in the phosphitylating reagent.
It was known from peptide synthesis experiments that the ortho-nitrophenylethyl caging group is
stable to strong acid (Chapter 2). Thus, a phosphoramidite was synthesized with the transient
acid-labile tert-butyl protecting group. In an initial attempt to synthesize the phosphoramidite
20, a dichlorophosphoramidite was treated with tert-butyl alcohol and ortho-nitrophenylethyl
alcohol in sequences with various solvents, concentrations, equivalents, and temperatures
(Scheme 4.2). However, in every experiment a homo-di-substituted phosphoramidite resulted
rather than the desired mixed phosphoramidite.
Scheme 4.2 Attempted synthesis of 0-1-(2-nitrophenyl)ethyl-O'-tertbutyl-N,N-diisopropyl phosphoramidite, 20.
NOI7K
1_4, O-j< 20
N 1
'" N' P'Cl
I)-,.
NPE= nitrophenyl-ethyl
N' 02
0°2 11<
In a furlther attempt, hexaethyl phosphorus triamide 21 was used in place of the
dichlorophosphoramidite to decrease the reactivity of the trivalent phosphorus starting material
(Scheme 4.3). The less reactive starting material allowed each diethylamine substituent on
phosphorus to be replaced under controlled activation by 4,5-dicyanoimidazole 7 as seen in
Scheme 4.3. The progress of the reaction was monitored by 31P NMR, and the shifts relative to
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phosphoric acid ( = 0.00 ppm) are shown below each chemical species. First, 21 was activated
to 22 with just under one equivalent of 4,5-dicyanoimidazole, which was subsequently replaced
with the bulky tert-butoxy group to generate 23. Note that after incorporation of the t-butyl
alcohol, only one chemical species was detectable by 3 1 p NMR. As incorporation of 4,5-
dicyanoimidazole into 21 was very rapid, it is likely that 23 was the later structure shown with
both the t-butoxy and imidazole substituents; however, this intermediate could not be isolated for
further experiments. Addition of the secondary ortho-nitrophenylethyl alcohol to 23 gave the
desired mixed phosphoramidite 24 in 74 % isolated yield. It is of significance that reducing the
reactivity of the starting material does not completely eliminate the formation of the homo-di-
substituted phosphoramidites 25 and 26. Though these species persisted under all reaction
conditions, the desired mixed phosphoramidite 24 was the major product and was easily isolated
by silica gel column chromatography.
Scheme 4.3 Synthesis of 0-1-(2-nitrophenyl)ethyl-O'-tertbutyl-N,N-diethyl phosphoramidite, 24.
lNC.N NOIN
N. . N.- NN C N1 1 Ne.q 
rN. - ,rN. 
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THF, 25°C THF, 25°C
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Phosphoramidite 24 was employed in the synthesis of the appropriately activated serine
and threonine derivatives for coupling to the 3'-dinucleotide of the tRNA. Initially, the serine
and threonine derivatives were synthesized as in Scheme 4.4 (optimum yield for each reaction
shown). The commercially available amino acids, 27a or 27b, were converted to the 4-pentenoyl
amide derivatives with 4-pentenoic anhydride in the presence of N,N-diisopropylethylamine
(DIPEA). Next, the free acids were activated as the cyanomethyl esters 29a and 29b by slow
addition of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) in neat chloroacetonitrile. The hydroxyl
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groups were revealed by deprotection of the tert-butyl ethers in trifluoroacetic acid (TFA) with a
small amount of the cation scavenger triisopropylsilane (TIS). The free hydroxyl serine and
threonine intermediates 30a and 30b were phosphitylated with phosphoramidite 24 activated by
4,5-dicyanoimidazole. The phosphite intermediates were immediately oxidized to the more
stable phosphate species 31a and 31b with tert-butyl hydroperoxide. The fully protected
phosphate intermnediates were carried directly to the final deprotection before purification and
characterization. The transient t-butyl ester on the phosphate was removed under mildly acidic
conditions to generate the amino acid derivatives 32a and 32b in high yield. These caged
phospho-amino acids were coupled to the 3'-dinucleotide of the suppressor tRNA. The
analogous tyrosine derivative was synthesized using the phosphoramidite 4 (Chapter 2) via a
modified procedure;l since there is no labile proton ; to the caged phosphate on the tyrosine,
there was no risk of B-elimination of the phosphate.
Scheme 4.4 Synthesis of Na-4-pentenoyl-phospho(nitrophenylethyl)-L-serine cyanomethyl ester, 32a, and
Na-4-,pentenoyl-phospho(nitrophenylethyl)-L-threonine cyanomethyl ester, 32b.
RAll 0 R OJ< R O<
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94% 80% 59%
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30a, b 31a, b 32a,b
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The overall yield for the three-step synthesis of the threonine intermediate 30b was an
acceptable 59%; however, in the case of 30a, the yield was only 19%. Once all the serine
derivative had been consumed, an alternate route to 30a was undertaken (Scheme 4.5). Serine,
33, was selectively acylated on the free amine with 4-pentenoic anhydride in a basic solution of
sodium bicarbonate. The free acid 34 was then converted to the cyanomethyl ester 30a with
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chloroacetonitrile in a solution of anhydrous DMF and triethylamine. The synthesis was
modified from previously reported work8 and gives a (non-optimized) two-step yield of 32%,
which is an improvement over the original three-step route that yields only 19%.
Scheme 4.5 Alternate synthesis of Nc-4-pentenoyl-L-serine cyanomethyl ester, 30a.
0
H2~~ NOH K OH OHNaHCO3 O CICH2CN, NEt3 °H2 N OH N3 N OH . OCN
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63% 51%
33 34 30a
The caged phospho-amino acid derivatives were coupled to the 3'-dinucleotide of the
suppressor tRNA: 5'-phospho-2'-deoxycytidylyl-(3', 5')-phosphoadenosine, or pdCpA (35,
Scheme 4.6). The tetrabutylammonium salt of pdCpA (or activated pdCpA) was synthesized as
previously reported 2 with minor modifications as noted in the Experimental section. As seen in
Scheme 4.6, a cyanomethyl ester activated amino acid was coupled to the 2' or 3' hydroxyl
groups of the adenosine ribose ring of pdCpA in the presence of 250 mM tetrabutylammonium
salt. The ester linkage at the ribose ring can rapidly migrate between the 2' and 3' hydroxyl
groups, therefore it is sufficient to acylate either hydroxyl group; interconversion in aqueous
buffer at pH 7.3, 37 °C is rapid with t 2 = 1-1 s-.4
The coupling conditions described in the original literature is activated pdCpA with the
cyanomethyl ester in anhydrous DMF without any additives.4 These conditions produced no
product with the caged phospho-amino acids. Due to the negatively charged phosphate groups in
the pdCpA and the caged phospho-amino acids, bringing the two reactants together was a
challenge. A range of temperatures and concentrations of starting materials were tested (25 °C to
55 °C, and 40 mM to 200 mM), however suitable conditions could not be identified. Adding an
excess of dry NBu 4OAc salt to a 100 mM solution of the reactants in DMF at room temperature
finally permitted some reaction to take place. The NBu4OAc additive afforded the desired
product, but also yielded a significant amount of 1-elimination side-product with the serine and
threonine derivatives. Therefore, a range of NBu 4OAc concentrations (10 mM to 500 mM) was
tested to determine the concentration yielding the highest desired product to -elimination
product ratio. Lower concentrations afforded no product, while 500 mM gave mostly -
elimination product. Starting materials in a solution of 250 mM NBu4OAc yielded the acylated
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Scheme 4.6 Synthesis of amino acyl-pdCpAs, 36a, 36b, and 37.
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dinucleotide as the major product, and thus this condition was used for all further coupling
reactions. It is likely that the tetrabutylammonium cation of the additional salt acts to neutralize
and solubilize the phosphate charges of the starting materials. Additionally, the extra base
produced by the salt at high concentrations is probably the culprit behind the -elimination side
products. The corresponding caged phospho-serine, threonine, and tyrosine Na-4-pentenoyl
protected acylated dinucleotides (4PO-cpAA-pdCpAs) were characterized by HPLC and
electrospray ionization mass spectrometry (ESI-MS) (36a, 36b, and 37, respectively).
4-2. Semi-synthesis and Molecular Biology
To generate the full-length suppressor tRNA acylated with the caged phospho-amino
acids (tRNAcACPIAs) an appropriate truncated tRNA for ligation is necessary. The glutaminyl
Tetrahymenya thermophila derived amber codon suppressor tRNA TH73G behaves orthogonally
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Figure 4.3. Semisynthesis of acylated suppressor tRNA. A plasmid containing the gene for the
TH73G tRNA is linearized by restriction digest; the linear template allows in vitro runoff transcription
to biochemically synthesize the tRNA with the last two 3'-bases absent. The promiscuous T4 RNA
ligase ligates the chemically acylated dinucleotide to the 3'-end of the tRNA, yielding full length
acylated suppressor tRNA.
in eukaryotic translation systems9 which is important for mammalian protein translation (see 4-3
below). The general semi-synthesis procedure to generate tRNAcACPAAs is depicted in Figure 4.3.
The TH73G plasmid was amplified in DH5ac cells, purified by standard techniques, and digested
with FokI just after the TH73G gene; this allowed the RNA polymerase to synthesize uniform
tRNAs by falling off the template just after the gene was transcribed. Run off transcription from
the linear DNA template produced the 74-mer tRNACuA-CA which contained the corresponding
amber anti-codon loop (CUA) and was missing the two 3'-terminal nucleotides (-CA). Upon ligation
of the 4PO-cpAA-pdCpAs to the tRNAcUA-cA with the promiscuous T4 RNA ligase, the full-
length 76-mer tRNACUACPAAs were formed. The product tRNAcuACPAAs were confirmed by matrix
assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF MS),
electrospray ionization time of flight mass spectrometry (ESI-TOF MS), or denaturing
polyacrylamide gel electrophoresis (D-PAGE). MALDI-TOF spectra were clear and no
deconvolution of data was necessary to visualize the ligated tRNA from the starting material or
any hydrolysis products.' Unfortunately, acquiring these spectra was difficult, and therefore ESI-
TOF and D-PAGE analyses were used in combination to confirm the complete formation of the
product tRNACA cPAAs.
Along with the full-length tRNACACPAAs, the other unique component of the suppression
reaction is mRNA with an amber codon at an appropriate site. The general molecular biological
scheme to generate this mRNA is shown in Figure 4.4. First, the amber codon is introduced into
a plasmid containing the target gene via oligonucleotide directed mutagenesis. Next, the DNA
template is linearized at the 3'-terminus of the gene using a restriction digest; again this allows
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the RNA polymerase to synthesize uniform mRNA strands by dropping off the template just
after the gene is transcribed. The mRNA containing the amber codon is biochemically
synthesized in vitro by run off transcription.
AGA TAG TAG
Oligonucleotide I UA
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Figure 4.4. Biochemical synthesis of mutant mRNA. The plasmid with the target gene is mutated using site-
directed mutagenesis techniques to introduce the amber stop codon at the desired position. The plasmid is
linearized by restriction enzymes just after the original stop codon of the gene. In vitro runoff transcription
produces the full-length mutant mRNA containing the amber stop codon.
A mutant nAChR-cc A122Z plasmid was prepared as previously reported. °10 A mutant
mrnVASP S153Z plasmid was prepared by converting serine 153 to the amber codon TAG via
oligonucleotide-directed mutagenesis. The gene was cloned into a vector with a 6XHis tag at the
N-terminus of the protein. For a discussion of the purification tag and its placement, see Chapter
5. Each mRNA was produced by run-off transcription and confirmed by glyoxal-agarose gel
electrophoresis.
4-3. Protein synthesis
In the nonsense suppression methodology, protein synthesis is often accomplished
separately from transcription and frequently in an in vitro translation system. There are several in
vitro systems available, and selection depends on the nucleic acid sequence encoding the protein
and the scale of synthesis desired. In general, the translation systems are extracts from E. coli,
rabbit reticulocytes, or wheat germ. The extracts contain the ribosomal elements, energy system
(creatine phosphate and creatine phosphokinase), tRNAs and tRNA synthetases from that
species, and elongation and release factors from that species necessary for protein translation.
Amino acids are added separately to the system; therefore, radiolabeled amino acids may be
selectively added for analysis of proteins synthesized exclusively from added mRNA. There are
examples of nonsense suppression in which the protein was translated in Xenopus oocytes and
the protein studied within the context of the living cell." Additionally, coupled or linked
transcription/translation systems from the aforementioned organisms are commercially available
in which plasmid or linear DNA is the nucleic acid template for protein synthesis, obviating the
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purification of intermediate mRNA. However, experience has shown that these systems are less
efficient in nonsense suppression reactions. 2
The original methodology describes the use of an E. coli extract system.2 This system is
ideal for prokaryotic proteins and those eukaryotic proteins that do not contain a significant
number of E. cli rare codons in the nucleic acid sequence. Rare codons are those that may
appear infrequently in an organism's genome.'3 For example, a common mammalian codon for
proline is CCC. This is a rare codon in E. coli, and E. coli do not produce many prolyl-tRNAs
with the cognate GGG anticodon. If a mammalian protein with few prolines encoded by CCC is
translated in an E. coli derived system, the protein could potentially be synthesized without a
problem. However, if a mammalian protein with multiple proline residues encoded by CCC is
translated in an E. coli derived system, there will not be sufficient tRNAcoGPr°s available, and
truncation products are likely to be a significant problem. In such a case, a eukaryotic derived
system, such as wheat germ or rabbit reticulocyte, should be used. Additionally, the scale of
protein synthesis required will affect the system used. Typical analysis reactions (50 [tL scale)
produce low nanogram quantities of protein and are accessible through any system. However, E.
coli and wheat germ extracts can be prepared on larger scales, such that milliliter scale reactions
may be performed to produce micro- to milligram quantities of protein.' Further, translations
may be run in dialysis systems such that nutrients can be continually fed into the system as a
concentrated protein sample is synthesized.'5
The mVASP protein is of mammalian origin and contains several sections of proline rich
domains encoded by the CCC codon. Therefore, analytical translation experiments were
performed in a rabbit reticulocyte translation system. While useful for preliminary analysis, this
system is not amenable to large-scale protein preparations due to the cost and difficulty of
obtaining cell preparations. Therefore, future work will focus on the preparation of large-scale
protein synthesis using a wheat germ system (Chapter 6).
Both mVASP and nAChR wild-type (WT) proteins were synthesized as controls in an in
vitro rabbit reticulocyte lysate translation system. The primary antibody used to detect mVASP
by western blot analysis was rabbit derived; therefore, it was necessary to purify the protein from
the rabbit system in order to probe with an anti-rabbit secondary antibody. The protein was
purified using the N-terminal 6XHis-tag and nickel-nitrilotriacetic acid (Ni-NTA) as described in
the Experimental section. Detection using the less sensitive anti-His6 antibody was not possible
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Figure 4.5. Western blot analysis a
of nAChR-WT and mVASP-WT
proteins. a) nAChR was detected
by an HA-epitope tag and loaded
onto SDS-PAGE within the
translation mixture. b) mVASP
was detected with a rabbit-derived
polyclonal anti-body after
purification from the translation
mixture.
b
*s.?.-I ' e.?
because the amounts of protein produced using this system were so small. Detection of nAChR
'was not complicated by the use of the rabbit derived system; protein purification was
unnecessary and the protein was detected within the translation mixture. As seen in Figure 4.5,
both nAChR-WT and mVASP-WT appeared as well defined bands by their respective western
blot analysis.
Nonsense suppression reactions were performed as depicted in Figure 4.6. The 4-
pentenoyl amine protecting group on the charged tRNA was removed in iodine and water at
room temperature for ten minutes, then immediately combined with the mRNA and other
translation components. The reactions were allowed to incubate at 30 °C for up to three hours in
the dark before being stored at -80 °C to prevent degradation. Test suppressions, in which a free
serine, phosphoserine, free threonine, phosphothreonine, free tyrosine, or phosphotyrosine was
introduced at the amber codon, used an amino acyl tRNA charged with an NVOC-protected
amine. The NVO(C group was removed by irradiation ( = 365 nm) for five minutes at room
temperature, and then immediately added to the remaining translation components as with the
caged phospho-amino acid suppression experiments.
Initial suppression experiments with the caged phospho-amino acids were performed with
nAChR-cc A1 22Z mRNA. ° The nAChR-a is known to accept non-natural amino acids in several
)positions using the suppression method. The nAChR-a A122Z transcript was introduced to the
translation system with either uncharged full-length tRNACUA, tRNACUA Thr, Tyr tRNAcuAPr pThr,
pryr, or tRNAcUACsCer cpThr, orcpTyr. As seen in Figure 4.7, the suppression reactions were successful in
all cases. The incorporation of the caged phospho-amino acids was particularly satisfying as
previous experiments have demonstrated poor incorporation efficiency with phospho-amino
acids.16' 17 While the suppression with the tRNACACPAAs is less efficient than with the free
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Figure 4.6. Nonsense suppression reaction with 4PO-protected tRNA. The suppressor tRNA is
deprotected with iodine in water immediately prior to addition to the in vitro translation system. In the
presence of the mutant mRNA, the tRNA suppresses the amber codon to incorporate the unnatural
amino acid at the desired site.
hydroxyl-amino acids, there is still significant translation of full-length protein. The lower
suppression efficiency of the tRNACUACPAAs may be due to a lowered affinity of the elongation
factors to tRNA with negatively charged amino acids. Ulhenbeck and coworkers have
demonstrated that there is a thermodynamic compensation among the backbone of the acceptor
and T helices of the tRNA, the amino acid with which it has been charged, and the elongation
factors (i.e., EF-Tu) involved in polypeptide elongation.' s8 19 It highly likely that this balance is
offset with a TH73G tRNACuA that has been acylated with a negatively charged amino acid.
Also, glutaminyl tRNAs (from which TH73G was derived) have a low inherent EF-Tu affinity.8 '
20 Therefore, a possible future endeavor may be to evolve tRNACUA species that reestablish the
thermodynamic balance when acylated with negatively charged amino acids.
No aa Tr cTvr Tvr Ser cSer Ser Thr cThr Thrmm, 
Figure 4.7. Suppression of nAChR-a A122Z.' nAChR-a A122Z mRNA was translated with tRNACUA
acylated with the amino acid above each lane. "No aa" refers to full-length tRNACuA that has not been
acylated with an amino acid.
Next, suppression reactions were performed using mVASP S153Z mRNA. The transcript
was introduced to the translation system with either uncharged full-length tRNACuA, tRNACUASer
or tRNACACPSer. As seen in Figure 4.8, the suppression reactions were successful. The
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incorporation of caged phosphoserine at position 153 was especially encouraging because this
protein was not known to accept non-natural amino acids in general, let alone at a critical
position for protein function (see Chapter 5).
WT No aa Ser cpSer
Figure 4.8. Suppression of mVASP S153Z. mVASP S153Z mRNA was translated with tRNACUA
acylated with the amino acid above each lane. "No aa" refers to full-length tRNAcUA that has not been
acylated with an amino acid. A mVASP-WT lane was run for a control.
Conclusion
The successful development of a method to incorporate caged phospho-amino acids into
full-length proteins has been described. A new phosphoramidite reagent was employed in the
synthesis of the caged phospho-amino acid analogs with the obligatory protecting groups for
coupling to the 3'-dinucleotide of a truncated suppressor tRNA. Full-length suppressor tRNAs
charged with caged phospho-amino acids were effectively incorporated into a test protein,
nAChR-a. Additionally, caged phosphoserine was successfully incorporated into the phospho-
regulated protein mVASP in place of the critical residue, S153. The availability of this
methodology allows the incorporation of caged phospho-amino acids via nonsense codon
suppression into any position of a full-length protein without requiring other modifications or
mutations to the protein.
Experimental
4-0. General Synthetic Procedures
All chemicals were purchased from Aldrich unless otherwise noted in the text; all
anhydrous reagents were prepared as described in Chapter 2. All NMR spectroscopy and HPLC
analysis and purification were performed as described in Chapter 2. DEPC dH 20 for use with
RNA is dH20 mixed with 0.1 % (v/v) diethyl pyrocarbonate overnight at room temperature, then
autoclaved for one hour. In order to prevent aberrant RNase degradation of samples, all RNA
samples (and other reagents to be used with RNA) were handled with aerosol barrier
micropipette tips and DEPC-treated water in a separate space where fresh gloves were worn at
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all times. Additionally, all RNA samples were stored dry at -80 C when possible to further
prevent RNase or chemical degradation.
4-1. Chemical Synthesis
0-1-(2-nitrophenyl)ethyl-O'-tertbutyl-N,N-diethyl phosphoramidite (24). To an oven dried flask
with stir bar, hexaethyl phosphorus triamide (1.37 mL, 5.00 mmole) and 4,5-dicyanoimidazole
(0.58 g, 4.90 mmole) were dissolved in anhydrous tetrahydrofuran (THF, 15 mL) under inert
atmosphere. In an oven dried pear-shaped flask, tert-butyl alcohol (0.48 mL, 5.00 mmole) was
dissolved in anhydrous THF (5.0 mL). In a separate oven dried pear-shaped flask, 1-2-
(nitrophenyl)ethyl alcohol (1.00 g, 6.00 mmole) was dissolved in anhydrous THF (1 mL). The
tBuOH solution was delivered to the phosphoramidite mixture via cannula, and the reaction was
allowed to stir at room temperature for 15 minutes, at which point the nitrophenylethyl alcohol
mixture was delivered to the reaction flask via cannula. The mixture was allowed to stir
overnight in the dark at room temperature. The mixture was then concentrated under reduced
pressure, and re-dissolved in ethyl acetate (EtOAc, 150 mL). The organic solution was washed
with 20% sodium bicarbonate (NaHCO 3, 2 x 150 mL) and brine (1 x 150 mL), then dried over
magnesium sulfate (MgSO4), filtered, and concentrated. The final product was purified by silica
gel flash chromatography (98:2 hexanes/triethylamine (NEt3), R: 0.73,) to give 24 (1.27 g) in
74.0 % yield. H NMR (300 MHz, CDCl3) b ppm: 7.92 (td, JH = 1.8 Hz, JHH = 8.4 Hz, 2H), 7.65
(tt, JHH = 1.5 Hz, JHH = 7.5, 1H), 7.40, (tt, JHH = 1.5 Hz, JHH = 8.4 Hz, 1 H), 5.55 (m, 1 H), 3.06
I'm, 4H), 1.57 (dd, JHH = 4.5 Hz, JHH = 6.3 Hz, 3H), 1.30 (d, JHH = 19.5 Hz, 9H), 1.08 (dt, JHH = 6.0
Hz, JHH =43.5 Hz, 6 H). 13C NMR (125.8 MHz, CDCl3) 147.9, 142.3 (d, Jpc = 1.7 Hz), 142.0 (d,
JFc = 2.3 Hz), 133.8 (d, Jpc = 6.3 Hz), 129.6 (d, Jpc = 6.9 Hz), 128.2, 124.5 (d, Jc = 12.1 Hz),
75.5 (dd, Jpc = 12.2 Hz, Jpc = 10.9 Hz), 67.0 (dd, Jpc = 15.5 Hz, Jpc = 8.6 Hz), 38.3 (d, Jpc = 21.2
Hz), 31.3 (dd, J = 8.6 Hz, Jpc = 4.5 Hz), 25.9 (dd, JPc = 10.3 Hz, Jc = 3.4 Hz), 15.6 (dd, Jpc =
20.8 Hz, JPc = 3.4 Hz). 31P NMR (121.5 MHz, CDCl3) 6 ppm: 139.93, 139.16 (diastereomeric
mixture). Product is not stable to MS measurements. See spectra 4,1, 4.2, and 4.3.
N-4-pentenoyl-L-serine cyanomethyl ester (30a) was synthesized by Method A or B:
Method A:
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N'-4-pentenoyl-O)-tert-butyl-L-serine (28a): H-O-tert-butyl-L-serine (27a, 500 mg, 3.10 mmole)
and N,N-diisopropylethylamine (DIPEA, 633 FtL, 3.70 mmole) were dissolved in THF (30 mL)
and water (30 mL). 4-pentenoic anhydride (676 tL, 3.70 mmole) was dissolved in THF (2 mL),
and added to the serine solution. The reaction was monitored by TLC (1:1:0.01
hexanes/EtOAc/acetic acid (AcOH), Rf = 0.30), stained with iodine and ninhydrin. After the
disappearance of starting material, the THF was removed under reduced pressure, and the water
layer extracted with EtOAc (3 x 100 mL). The organic portions were dried over MgSO4, filtered
and concentrated under reduced pressure. The product was purified by silica gel flash
chromatography (827 mg) in 93.7% yield. H NMR (300 MHz, CDCl3) ppm: 6.99 (d, JHH = 8.1
Hz, H), 5.70 (, 1 H), 4.94 (q, JHH = 17.1, 10.2, 10.2 Hz, 2 H), 4.64 (m, 1 H), 3.71 (dd, JHH = 9
Hz, JHH = 3 Hz, 1 H), 3.46 (dd, JHH = 9.3 Hz, JHH =3 Hz, 1 H), 2.25 (s, 4 H), 0.99 (s, 9 H). 3C
NMR (125.8 MHz, CDCl3 ) ppm: 176.0, 173.9, 136.7, 115.8, 73.7, 61.9, 53.0, 35.3, 29.7, 27.3.
]ESI-MS: [M-H]- 242.1401 (obsd), 242.1398 (calcd). See spectra 4.4 and 4.5.
N-4-pentenoyl-O()-tert-butyl-L-serine cyanomethyl ester (29a): N-4-pentenoyl-O-tert-butyl-L-
serine (825 mg, 3.39 mmole) was dissolved in chloroacetonitrile (644 L, 10.20 mmole), and
cooled to 0°C, stirring, under argon. Diazabicyclo[5.4.0]undec-7-ene (DBU, 507 [tL, 3.39
mmole) was slowly added to the stirring mixture. The reaction was allowed to warm to room
temperature, and stir overnight under argon. The reaction mixture was diluted with EtOAc (150
mL), washed with water (2 x 150 mL), then brine (1 x 150 mL), dried over MgSO 4, filtered and
concentrated (1: 1L hexanes/EtOAc, Rf = 0.41) (765 mg, 79.9%). H NMR (300 MHz, CDC13) 
ppm: 6.81 (d, JHh,= 8.7 Hz, 1 H), 5.83 (m, 1 H), 5.11 (q, JHH= 18.3, 6.6, 9.9 Hz, 2 H), 4.84 (m, 3
H), 3.86 (dd, JHH = 9.3 Hz, JHH = 3.3 Hz, 1 H), 3.58 (dd, JHH = 9.3 Hz, JHH = 3.3, 1 H), 2.38 (s, 4
H), 1.16 (s, 9 H). 3C NMR (125.8 MHz, CDCl3 ) ppm: 172.7, 169.6, 137.1, 115.7, 114.5, 73.8,
61.9, 52.7, 49.2, 35.2, 29.5, 27.3. ESI-MS: [MNa] + 305.1478 (obsd), 305.1472 (calcd). See
spectra 4.6 and 4.7.
N'-4-pentenoyl-L-serine cyanomethyl ester (30a): N-4-pentenoyl-O-tert-butyl-L-serine
cyanomethyl ester (750 mg, 2.69 mmole) was dissolved in an ice-cold solution of triflouroacetic
acid (TFA) with 1 % (v/v) triisopropylsilane (TIS). The reaction was stirred at 0°C for 4 hours,
and determined complete by TLC (EtOAc, Rr = 0.43). The reaction mixture was poured into ice-
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cold saturated NaHCO3 (250 mL) and EtOAc (120 mL). The organic layer was washed with
saturated NaHCO3 (3 x 100 mL), then brine (1 x 100 mL), dried over MgSO4 , filtered, and
concentrated under reduced pressure. The mixture was purified by silica gel flash
chromatography to give the product (156 mg) in 25.6% yield. H NMR (300 MHz, CDC13) b
ppm: 6.90 (d, JI, = 7.8 Hz, 1 H), 5.87 (m, 1 H), 5.10 (t, JHH = 19.5, 10.8 Hz, 2 H), 4.80 (d, JHH =
1.5 Hz, 3 H), 4.70 (m, 1 H), 4.06 (dd,JHH= 11.7 Hz, JHH= 3.6, 3.3 Hz, 1 H), 3.87 (dd,JHH= 11.4
Hz, JH = 3.6, 3.6 Hz, 1 H), 2.38 (d, JHH = 3.0 Hz, 4 H). 13C NMR (125.8 MHz, CDC13) ppm:
173.5, 169.8, 1377.0, 116.4, 114.5, 63.0, 54.6, 49.7, 35.8, 29.8. ESI-MS: [MNa] + 249.0847 (obsd),
249.0846 (calcd). See spectra 4.8 and 4.9.
Method B:
Modified from reference 8.
N'-4-pentenoyl-z-serine-OH (34): H-O-L-serine (33, 500 mg, 4.75 mmole) and sodium
bicarbonate (560 mg, 6.66 mmole) were dissolved in water (60 mL) and hexanes (30 mL),
rapidly stirring at room temperature. The anhydride (1.22 mL, 6.66 mmole) was dissolved in 1,4-
dioxane (15 m) and added in one portion to the serine/base mixture. The reaction was
monitored by TLC in 65:25:4 CHCl3/MeOH/dH2O (Rf = 0.19)(stained with ninhydrin or iodine),
and determined complete after two hours. The reaction was quenched with dH2O (pH=l with
HCl, 250 mL), and extracted with CH 2 C12 (250 mL). The aqueous layer was then extracted with
2 x 100 mL CH2C 2. Saturated NaCl was then added to the aqueous layer (350 mL), which was
extracted with THF (3 x 150 mL). The THF portions were combined, dried over MgSO4, filtered,
and concentrated under reduced pressure to give the product in 63.4% yield (564 mg). H NMR
(300 MHz, D2 0) 6 ppm: 5.81 (m, 1H), 5.00 (m, 2H), 4.41 (m, 1H), 3.87 (m 2H), 2.31 (m, 4H).
See spectrum 4.10.
N-4-pentenoyl-L-serine cyanomethyl ester (30a): N-4-pentenoyl-L-serine-OH (564 mg, 3.01
mnmole) was dissolved in anhydrous DMF (16.7 mL) under argon at room temperature and left
stirring. Triethylamine (1.26 mL, 9.03 mmole) was added to the stirring solution.
Chloroacetonitrile (8.4 mL, 133 mmole) was slowly added to the stirring serine solution, and
allowed to mix overnight at room temperature under argon. The reaction was determined
complete by TLC in 65:25:4 CHCl3/MeOH/dHO (Rf = 0.84) (stained with iodine). The reaction
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mixture was concentrated under reduced pressure, then re-dissolved in EtOAc (200 mL) and
water (100 mL). The organic layer was washed with water (2 x 100 mL) then brine (1 x 100
rnL), dried over MgSO4, filtered, and concentrated under reduced pressure. The product was
purified by silica gel flash chromatography (EtOAc, Rf = 0.33) to give the pure product in 51%
yield (345 mg). H NMR (300 MHz, CDC13) ppm: 6.67 (d, JHH = 7.5 Hz, 1 H), 5.89 (m, 1H),
5.13 (tdd, JHH = 18.6 Hz, JHH = 1.5 Hz, JH = 1.2 Hz, 2H), 4.82 (d, JHH = 3.0 Hz, 2H), 4.76 (m,
1 H), 4.09 (m, 2H), 3.09 (bs, 1H), 2.42 (m, 4H). See spectrum 4.11.
N'-4-pentenoyl-phospho(O-nitrophenylethyl-O'-tert-butyl)-L-serine cyanomethyl ester (31a):
A¢'-4-pentenoyl-L-serine cyanomethyl ester (30a, 150 mg, 663 [tmole) was dissolved in
anhydrous THF (2.0 mL), in a round bottom flask fitted with an oven dried stir bar under argon.
In a separate pear flask, 0-1-(2-nitrophenyl)ethyl-O'-tertbutyl-N,N-diethyl phosphoramidite (24,
340 mg, 995 itrnole) and 4,5-dicyanoimidazole (157 mg, 1.33 mmole) were dissolved in
anhydrous THF (1.3 mL), and kept dark. The phosphoramidite solution was delivered to the
serine solution via syringe, and the reaction was allowed to stir overnight, under argon, in the
dark. The reaction was judged complete by loss of starting material by TLC. The mixture was
concentrated under reduced pressure, and redissolved in EtOAc (50 mL). The organic layer was
washed with 10%i NaHCO3 (2 x 80 mL), brine (1 x 80 mL), then dried over sodium sulfate
(Na2SO4), decanted and concentrated. The phosphite mixture was then oxidized with tert-butyl
hydroperoxide (tBuOOH, 266 tL of 5 M solution in decane, 1.33 mmole) in dichloromethane
(CH2C12, 10 mL) for one hour, in the dark. The mixture was diluted with CH2C12 (50 mE), and
washed with 10% NaHCO3 (2 x 80 mL) and brine (1 x 80 mL), then dried over MgSO4, filtered
and concentrated. The product was partially purified by silica gel flash chromatography (1:2
hex/EtOAc, Rf = (0.26), and carried on to the next step before final purification (68.2%).
N-4-pentenoyl-phlospho(nitrophenylethyl)-L-serine cyanomethyl ester (32a): N-4-pentenoyl-
phospho(1-nitrophenylethyl-2-tert-butyl)-L-serine cyanomethyl ester (69 mg, 135 [tmole) was
dissolved in acetonitrile (MeCN, 4.0 mL) at room temperature, stirring, and kept dark. A solution
of TFA (1.0 mL) with TIS (50 tL) was added to the solution, and stirred for 10 minutes at room
temperature. The mixture was then poured into ice-cold saturated NaHCO3 (4.0 mL). The
product mixture was purified by reverse phase HPLC. (93:7 to 0:100 water/MeCN/0.1% TFA,
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over 35 minutes, R, = 22.68 min) in 99% yield (61.0 mg). 'H NMR (300 MHz, CDCl 3 ) ppm:
8.00 (ddd, JHH = 8.1 Hz, JHH = 3.6, 3.6 Hz, JHH = 1.5, 1.2, 1.2, 1.5 Hz, 1 H), 7.79 (m, 2 H), 7.53
(m, 1 H), 6.04 (, 1 H), 5.86 (m, 1 H), 5.11 (m, 2 H), 4.88 (m, 3 H), 4.40 (m, 3 H), 2.40 (d, JHH =
7.5 Hz, 4 H), 1.71 (dd, JHH = 6.3 Hz, JHH = 1.2, 1.2 Hz, 3 H). 3C NMR (125.8 MHz, CDC1 3 ) 6
]ppm: 173.7 (d, JC = 4.5 Hz), 168.3, 147.3, 137.5, 137.0, 134.6 (d, Jpc = 8.7 Hz), 129.5 (d, JPc =
1.8 Hz), 128.2 (d, Jpc = 2.4 Hz), 125.0 (d, Jpc = 2.9 Hz), 116.3 (d, Jc = 3.4 Hz), 114.2, 73.3,
657.2, 52.8 (d, JC = 6.3 Hz), 50.1 (d, Jpc = 7.4 Hz), 35.5 (d, Jpc = 3.5 Hz), 29.7 (d, Jpc = 2.3 Hz),
24.7 (m). 3 P (121.5 MHz, CDC 3): -1.382. ESI-MS: [M-H]- 454.1017 (obsd), 454.1021 (calcd).
See spectra 4.12, 4.13, and 4.14.
N~-4-pentenoyl-O-tert-butyl-L-threonine (28b): H-O-tert-butyl-L-threonine (27b, 500 mg, 2.85
mnmole) and DIPEA (683 tL, 3.99 mmole) were dissolved in THF (40 mL) and water (10 mL).
4-pentenoic anhydride (730 tL, 3.99 mmole) was dissolved in THF (5 mL), and added to the
threonine solution. The reaction was monitored by TLC (1:1:0.01 hexanes/EtOAc/AcOH, Rf =
0.31), stained with iodine and ninhydrin. After the disappearance of starting material, the mixture
was concentrated under reduced pressure, and the product was purified by silica gel flash
chromatography (625 mg, 85.3%). H NMR (300 MHz, CDC1 3) ppm: 6.74 (d, JHH = 8.4 Hz, 1
H), 5.88 (m, 1 H), 5.12 (q, JHH = 17.4, 8.1, 10.2 Hz, 2 H), 4.60 (dd, JHH = 8.7 Hz, JHH = 2.7, 2.4
Hz, 1 H), 4.32 (m, 1 H), 2.43 (m, 4 H), 1.20 (s, 9 H), 1.71 (d, JHH = 6.6 Hz, 3 H). 3C NMR
(125.8 MHz, CDC13) b ppm: 174.3, 174.0, 136.9, 116.0, 75.2, 67.2, 57.7, 35.6, 29.7, 28.4, 20.1.
ESI-MS: [M-H]- 256.1551 (obsd), 256.1554 (calcd). See spectra 4.15 and 4.16.
N~-4-pentenoyl-O-tert-butyl-L-threonine cyanomethyl ester (29b): N"-4-pentenoyl-O-tert-butyl-
L.-threonine (390 mg, 1.51 mmole) was dissolved in chloroacetonitrile (478 tL, 7.55 mmole) and
cooled to 0°C, stirring, under argon. DBU (226 RL, 1.51 mmole) was slowly added to the stirring
mixture. The reaction was allowed to warm to room temperature, and stir overnight under argon.
The reaction mixture was diluted with EtOAc (100 mL), washed with water (2 x 100 mL) and
brine (1 x 100 mL), then dried over MgSO 4, filtered and concentrated (1:1 hexanes/EtOAc, Rf =
0.43) (321 mg, 71.7%). H NMR (300 MHz, CDC13) b ppm: 6.39 (d, JHH = 9.0 Hz, 1 H), 5.91 (m,
1 H), 5.14 (q, JHh = 17.1, 7.5, 10.2 Hz, 2 H), 4.78 (d, JHH = 3.0 Hz, 2 H), 4.61 (dd, JHH = 9.3 Hz,
1H = 2.1, 1.8 Hz. 1 H), 4.27 (m, 1 H), 2.42 (d, JHH = 2.7 Hz, 4 H), 1.21 (d, JHH = 6.3 Hz, 3 H),
89
1.14 (s, 9H). '3C NMR (125.8 MHz, CDC13) 6 ppm: 173.1, 169.9, 137.1, 115.9, 114.3, 74.5, 67.2,
57.7, 49.1, 35.5, 29.5, 28.6, 21.0. ESI-MS: [MNa]* 319.1617 (obsd), 319.1628 (calcd). See
spectra 4.17 and 4.18.
N-4-pentenoyl-L-threonine cyanomethyl ester (30b): N-4-pentenoyl-O-tert-butyl-L-threonine
cyanomethyl ester (315 mg, 1.06 mmole) was dissolved in an ice-cold solution of TFA with 1%
(v/v) TIS. The reaction was stirred at 0°C for two hours, and determined to be complete by TLC
(1:1 hex/EtOAc, Rf = 0.15). The reaction mixture was poured into ice-cold saturated NaHCO3
(80 mL) and EtOAc (80 mL). The organic layer was washed with saturated NaHCO 3 (2 x 80 mL)
and brine (1 x 80 mL), then dried over MgSO4, filtered, and concentrated under reduced
pressure. The mixture was purified by silica gel flash chromatography to give the product (150
mg) in 59.0% yield. H NMR (300 MHz, CDC13) ppm: 6.39 (d, JHH = 8.4 Hz, 1 H), 5.90 (m, 1
H), 5.14 (t, JHH = 17.4, 13.8 Hz, 2 H), 4.87 (q, JHH = 15.6, 7.5, 15.6 Hz, 2 H), 4.69 (dd, JHH = 9.0
Hz, JHH = 2.7, 2.4 Hz, 1 H), 4.46 (qd, JHH = 6.3, 6.3, 6.3 Hz, JHH = 2.4, 2.4, 2.4, 2.4 Hz, 1 H), 2.43
(d, JHH = 2.7 Hz, 4 H), 1.27 (t, JHH = 4.2, 2.1 Hz, 3 H). ' 3C NMR (125.8 MHz, CDC13) ppm:
173.7, 170.2, 13'7.1, 116.4, 114.5, 68.0, 57.5, 49.6, 36.0, 29.8, 20.6. ESI-MS: [MNa]+ 263.1005
(obsd), 263.1002 (calcd). See spectra 4.19 and 4.20.
N'-4-pentenoyl-phospho(O-nitrophenylethyl-O'-tert-butyl)-L-threonine cyanomethyl ester (31b):
N-4-pentenoyl-L.-threonine cyanomethyl ester (140 mg, 582 [tmole) was dissolved in anhydrous
THF (2 mL), in a round bottom flask fitted with an oven dried stir bar under argon. In a separate
pear flask, 0-1-(2-nitrophenyl)ethyl-O'-tertbutyl-N,N-diethyl phosphoramidite (24, 299 mg, 874
lmole) and 4,5-clicyanoimidazole (137 mg, 1.16 mmole) were dissolved in anhydrous THF (1
mL), and kept dark. The phosphoramidite solution was delivered to the threonine solution via
syringe, and the reaction was allowed to stir overnight, under argon, in the dark. The reaction
was judged complete by loss of starting material by TLC. The mixture was concentrated under
reduced pressure., and re-dissolved in EtOAc (80 mL). The organic layer was washed with 10 %
NaHCO3 (2 x 80 mL), brine (1 x 80 mL), then dried over Na2 SO4, decanted and concentrated.
The phosphite mixture was then oxidized with tBuOOH (232 [tL of 5 M solution in decane, 1.16
rnmole) in dichloromethane (CH2Cl2, 10 mL) for one hour, in the dark. The mixture was diluted
with CH2C12 (70 mL), and washed with 10% NaHCO 3 (2 x 80 mE), brine (1 x 80 mE), then dried
90
over MgSO4, filtered and concentrated The product was partially purified by silica gel flash
chromatography (Rf = 0.19, 1:1 hex/EtOAc) and carried on to the next step before final
purification (70.1%).
N -4-pentenoyl-phospho(-nitrophenylethyl)-L-threonine cyanomethyl ester (32b): N-4-
pentenoyl-phospho(1-nitrophenylethyl-2-tert-butyl)-L-threonine cyanomethyl ester (250 mg, 476
tmole) was dissolved in MeCN (3.5 mL) at room temperature, stirring, and kept dark. A solution
of TFA (3.5 mL) with TIS (70 [tL) was added to the solution, and stirred for 15 minutes at room
temperature. The mixture was then poured into ice-cold saturated NaHCO3 (10 mL). The mixture
was purified by reverse phase HPLC (93:7 to 0:100 water/acetonitrile/0.1% TFA over 35
minutes, R, = 23.86 min) in 41.0% yield (92.0 mg). H NMR (300 MHz, CDC13) ppm: 8.00 (d,
.IH = 7,=.8 Hz, H), 7.79 (m, 2 H), 7.55 (m, 1 H), 6.89 (t, JHH = 7.2, 9.0 Hz, 1 H), 6.53 (bs, 1 H),
6.05 (m, 1 H), 5..87 (m, 1 H), 5.13 (m, 2 H), 4.92 (m, 6 H), 2.42 (d, JHH = 2.1 Hz, 4 H), 1.74 (d,
J.HH = 6.3 Hz, 3 H), 1.35 (dd, JHH = 24.0 Hz, JHH = 6.3, 6.6 Hz, 3 H). 3C NMR (125.8 MHz,
CDC13) ppm: 74.8, 169.1 (d, Jc = 6.3 Hz), 147.8 (d, Jpc = 12.1 Hz), 137.6 (t, Jc = 4.7 Hz),
137.0, 134.7 (d, Jpc = 2.3 Hz), 129.8, 128.5 (d, Jpc = 15.5 Hz), 125.2 (d, Jpc = 2.3 Hz), 116.8 (d,
JP = 3.4 Hz), 114.5 (d, Jpc = 4.7 Hz), 75.8 (t, Jpc = 5.8 Hz), 73.7 (t, Jpc = 5.2 Hz), 56.6 (dd, JpC =
5.8 Hz, Jp = 2.4 Hz), 50.5 (d, Jpc = 10.3 Hz), 35.9 (d, Jpc = 1.1 Hz), 30.1, 24.9 (dd, Jpc = 8.7 Hz,
1pc = 5.3 Hz), 19.2 (dd, Jpc = 9.2 Hz, Jpc = 2.3 Hz). 31p (121.5 MHz, CDC13): -1.13, -1.17. ESI-
MlS: [M-H]- 468.1168 (obsd), 468.1177 (calcd). See spectra 4.21, 4.22, and 4.23.
5'-Phospho-2'-deoxycytidylyl(3',5')phosphoadenosine (pdCpA, 35). pdCpA was synthesized as
previously reported with the following minor modifications.2 In phosphitylation steps, tetrazole
was replaced with 4,5-dicyanoimidazole. In oxidation steps, two equivalents of tBuOOH was
added to the reactant stirring in CH2C12 rather than using iodine in THF/water. The final
cleprotection of pdCpA was performed with 10% (v/v) aqueous ammonium hydroxide instead of
concentrated ammonium hydroxide (30% (v/v)). After final deprotection, the pdCpA was
purified by reverse phase preparatory HPLC in a 93:7 to 0:100 water:acetonitrile (0.1% TFA)
gradient over 35 minutes (tR -= 5.8 min), and no desalting step was necessary. The
tetrabutylammonium salt of pdCpA was prepared by ion exchange chromatography, as
described,2 and it was important to dissolve the dinucleotide in slightly acidic water before
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application to the column to ensure exchange of protons to tetrabutylammonium. The number of
equivalents of the counter ion was determined by H NMR (with an increased delay time to
correct for aromatic vs. aliphatic integrations). The phosphoramidite reagent O-Cytidylyl(N-
benzyl)-O-f-cyanoethyl-N,N-diisopropyl-phosphoramidite was purchased from SynGen, Inc.
(San Carlos, CA); the phosphoramidite reagent bis-O,O'--cyanoethyl-N,N-diisopropyl-
phosphoramidite was purchased from Toronto Research Chemicals (Toronto, Canada).
4PO-cpSer/cpThr/cpTyr-pdCpA (36a, 36b, 37): In general, pdCpA(NBu 4) 24 (10 mg, 8.2 [tmol),
4PO-cpAA-OCH 2CN (21 [tmole), and tetrabutylammonium acetate (NBu 4OAc) were placed
under vacuum overnight. The NBu 4OAc was made up to a 250 mM solution in anhydrous DMF.
This solution (100 tL) was used to dissolve the dinucleotide, and then the mixture was added to
the amino acid ester under nitrogen. The reaction was allowed to mix at room temperature under
nitrogen, and monitored by reverse phase HPLC. Upon complete loss of starting material, the
reaction was quenched with 2:1 water/acetonitrile (0.1% TFA) (1.5 mL). The reaction was
purified by preparative reverse phase HPLC, and confirmed by ESI-MS. The 4PO-
cpSer/cpThr/cpTyr-pdCpA was dissolved in DMSO and quantitated by UV (ma, A260 30,700 M-
cm'-), and stored at-80 C. 4PO-cpSer-pdCpA: R, = 23.23 min; ESI-MS: [MNa]+ 1059.0,
[MNaH]2+ 530.0 (obsd), 1057.7, 529.3 (calcd). 4PO-cpThr-pdCpA: R, = 23.40 min; ESI-MS:
[MNa]+ 1072.9, [MH]+ 1049.0 (obsd), 1072.7, 1049.7 (calcd). 4PO-cpTyr-pdCpA: R, = 25.80
min; ESI-MS: [MH]+ 1111.2, [M+2H]2+ 556.1 (obsd), 1111.0, 556.0 (calcd).
4-2. Semisynthesis and Molecular Biology
TH73G (tRNAcuA-cA). The gene for the tRNACUA-CA was received from the Dougherty Lab
(California Institute of Technology),9 amplified in chemically competent DH5a cells and
purified according to standard procedure. The plasmid DNA (343 tg) was linearized with FokI
restriction enzyme (New England Biolabs) according to manufacturer's recommendations. Upon
confirmation of digestion by analytical agarose gel electrophoresis, the DNA was purified by
phenol/chlorofornn/isoamyl (PCI) extraction. The tRNA was transcribed from the DNA template
using the T7-MEGAshortscript High Yield Transcription Kit (Ambion) according to the
nmanufacturer's protocol. The tRNA was purified by PCI extraction and precipitated with a 1:1
mixture of ethanol:isopropanol at -20°C for at least one hour. After centrifugation, aspiration,
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and drying, the pellet was dissolved in 0.1% DEPC-treated water and quantified by UV (RNA:
Concentration (g/mL) = A260/0.025). Aliquots of 20 [tg were made in DEPC-treated dH20 and
stored at-80 C. Additionally, 2% agarose analytical gel electrophoresis (stained with ethidium
bromide) revealed a single strong band at approximately 75 bp.
-CALigation to the tRNACuA-  was performed as follows:
1. 30 [tL of' 10 mM 4-(2-hydroxyethyl)-l1-piperazine-ethanesulfonic acid (HEPES), pH 7.5
was added to 30 [tg tRNACuA-CA in 15 [tL DEPC dH 2O.
2. This microfuge tube was placed in a beaker of boiling water, which was set in a bucket of
ice water. The sample was allowed to cool to ~ 37 °C (water temperature measured at the
top of the beaker where the sample was floating).
3. While the sample was cooling, the rest of the reaction was assembled:
o 1,2 tL pdCpA-aa, 3mM in DMSO
o 12 tL 10 X T4 RNA ligase buffer (New England Biolabs)
o 45 tL DEPC dH2O
o 6 [tL T4 RNA ligase (New England Biolabs, 20 U/[tL)
4. When the tRNA/HEPES was cooled to 37 °C, it was added to the reaction mixture, and
the contents briefly vortexed and centrifuged. The reaction was incubated at 37 °C for 2
hours.
5. The reaction was quenched by adding 17.5 tL DEPC dH 20 and 12.5 [tL 3.0 M NaOAc,
pH 5.0 (150 [tL total).
6. The amino-acyl tRNA was purified by PCI extractions as follows:
a. 150 tL 25:24:1 phenol/chloroform/isoamyl alcohol
b. 68.7 tL DEPC dH 2O + 6.3 [tL 3.0 M NaOAc, pH 5.0
c. 225 tL 24:1 chloroform/isoamyl alcohol
7. The combined aqueous layers were combined with 700 tL 1:1 EtOH/iPrOH, briefly
vortexed, and precipitated overnight by standing at - 20 °C.
8. Samples were recovered by microcentrifuging at maximum speed for 15 minutes at 4 °C.
9. The supernatant was removed by pipetting, and samples were dried under vacuum for 30
minutes.
10. Samples were stored dry at - 80 C until ready to de-salt, at which point they were
dissolved in 30 [tL mM NaOAc, pH 4.5, and desalted using BD Biosciences CHROMA
SPIN-30 DEPC dH2O columns (following manufacturer's instructions). The desalted
samples were quantified by measuring the UV A2 60 of a diluted sample, confirmed by
ESI-TOF MS, and stored at - 80 °C. (UV A26d0.025 = Concentration in [tg/mL)
MALDI-TOF MS measurements were preformed as reported.' For ESI-TOF MS measurements,
a PerSeptive BiosystemsTM Mariner Workstation was used. DNA samples were stocked in dH2O
(-100 rtM), tRNAcuA-CA samples were stocked in DEPC dH20 (- 350 [tM), and tRNACUACPAA
samples were stocked as above (20 tM). Samples were diluted to 5- 25 FM using 60:20:20
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MeCN/iPrOH/10) mM NH4OAc with 20 mM piperidine and 10 mM imidazole. The samples
were infused toward the detector using a syringe pump injector without heat, and detected in
negative ion mode. The data peaks were de-convoluted by hand as piperidinium salts of the
parent ion. The most accurate measurements were made with data corresponding to lower charge
states, and thus higher m/z ratios (above 1200.0 Da).
Exemplary data series are as follows:
tRNAcuA-CA: 1199.9 = [M+6pip-20]2 ° - tRNACUACPSer: 1466.2 = [M+5pip-17] 17 -
1332.9 = [M+6pip-18]' - 1567.3 = [M+7pip-16] 6 -
1410.2 = [M+6pip-17] 17- 1671.6 = [M+7pip-15]' 5-
1505.8 = [M+7pip-16]' 6 - 1661.1 = [M+Spip-15]1 5-
1599.9 = [M+Spipi-15] 15- 1793.0 = [M+7pip-14]' 4-
Additionally, the acylated tRNA was analyzed by Denaturing Polyacrylamide Gel
]Electrophoresis (D-PAGE): The general protocol and buffers can be found in "Current Protocols
in Molecular Biology; 2.12.1-2.12.7: Purification of Oligonucleotides Using Denaturing
Polyacrylamide Gel Electrophoresis" (http://www.interscience.wiley.com/cp/index.htm). Note:
even though the procedure states that a 6% gel will resolve a 70 bp oligonucleotide, the 74 or 76
bp tRNA samples ran near the bottom of the gel with no resolution.
More optimum gel conditions were as follows: 12% polyacrylamide, 1.5 mm thick, 10
well. A 0.5 tg sample of tRNA in ~10 [tL urea loading buffer was loaded per well. A 1:5
mixture of nucleic acid loading buffer (containing xylene blue, 5X)/urea loading buffer was
loaded on the outside lanes. The gel was run at 140V for 2 hours (until the xylene blue was
about 1 cm fromn the bottom of the plate; the bromophenol blue had dropped off a long time
before then). The gel was soaked in dilute ethidium bromide, which was sufficient to visualize
the tRNA on a transilluminator and capture an image for documentation.
nAChR cloning: The nAChR-a gene was prepared as previously reported 0
mVASP cloning: The mVASP gene was received from the Gertler Lab (Massachusetts
Institute of Technology) in a pBS-KSII vector with an upstream T5 promoter. The site specific
mutagenesis of Ser153TAG (S153Z, where Z represents the amber stop codon TAG) was
performed following the Stratagene QuikChange protocol and the following primers: sense 5'-
GAG CGC CGG GTC TAG AAT GCA GGA GGC CC; antisense 5'-GGG CCT CCT GCA
TTC TAG ACC CGG CGC TC. Underlined bases comprise the amber stop codon. Several
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colonies were picked for sequencing; one sample with the correct sequence was kept for further
use.
Both the WT and S153Z mVASP genes were amplified from the pBS-KSII vectors using
PCR with Pfu Turbo Polymerase (Stratagene, La Jolla, CA) and the following primers to include
an N-terminal 6XHis-tag: Forward 5'- CACC ATG CAT CAT CAT CAT CAT CAT GGA TCC
ATG AGC GAG ACG GTC ATC-3' Reverse 5'- TCA AGG AGA ACC CCG CTT CCT CAG-
3'. The products were purified by agarose gel electrophoresis and stored at -20 °C. The products
were then used in the TOPO directional cloning reaction as described by the manufacturer
(TOPO Directional Cloning: pcDNA3. 1/V5-His; Invitrogen, Carlsbad, CA). Colonies were
picked and plasmid DNA purified by standard procedure. The DNA was screened by a single
restriction enzyme digest: Sal I will cut the empty vector into two pieces, 2.3 and 3.2 kb in
length, while it will cut the pcDNA/mVASP vectors into two pieces, 2.1 and 4.4 kb in length.
Several samples with the insert were submitted for sequencing, and one of each plasmid sample
with the correct sequence was stored at -20 °C for future work. Plasmid names: pcDNA-His-
rnVASP-WT and pcDNA-His-mVASP-S153Z.
mRNA: Plasmid DNA of WT and S153Z mVASP was amplified in DH5a cells using
standard protocol. Approximately 100 [tg of each plasmid were linearized with PmeI (which cuts
directly after the non-amber stop codon), purified by agarose gel electrophoresis, and redissolved
in DEPC treated water. The mRNA was then transcribed from the templates using the Ambion
T7 mMessage mMachine® High Yield Capped RNA Transcription Kit (catalog # 1344). The
transcription reactions were set up according to manufacturer's protocol without the radiolabel
tracer. After incubation for two hours at 37 °C, and subsequent incubation with DNase I, the
reaction was quenched using water and ammonium acetate solution (0.1 final volume of 5 M
NH4OAc with 100 mM EDTA). The mRNA was purified and recovered using
phenol/chloroform/isoamyl alcohol extraction, quantified using UV: A260/0JO.025 = concentration
(ltg/mL), and stored in DEPC treated water at - 80 °C.
The mRNA was analyzed using glyoxal-agarose gels. Bis-Pipes-Tris-EDTA (BPTE)
buffer was prepared and stocked as a lOX solution at room temperature (note: no DEPC water
was necessary, as the mRNA was not recovered from the gels). The glyoxal reaction mixture was
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prepared according to literature procedure, and stored in small aliquots at - 80 OC.2' Briefly, the
procedure follows:
De-ionizing the Glyoxal:
Immediately before use, the glyoxal was passed through a small column of mixed-bed
ion-exchange resin (Bio-Rad AG-5 10-X8) and the pH of the eluent was monitored. Once the pH
was > 5.5, the glyoxal was used immediately, or stored in aliquots under N 2 at - 20 °C.
Glyoxal Reaction Mixture: USE EXTRA CAUTION WHEN HANDLING
DMSO 6 mL
e-ionized glyoxal 2 mL
10 X BPT'E buffer 1.2 mL
80 % glycerol in water 0.6 mL
ethidium bromide (10 mg/mL in dHO) 0.2 mL
Total 10 mL
Divide into small aliquots (100 to 200 tL), and store at - 80 °C.
To analyze the mRNA, the sample (at least 1 tg in 1 - 2 L) was mixed with 10 tL
glyoxal reaction mixture and incubated at 55 °C for one hour. Meanwhile, the agarose gel with 1
X BPTE buffer (1.5 % for 0.5 - 8.0 kb mRNA) was prepared. After incubation, the samples were
chilled in an ice bath for 10 minutes, and then centrifuged for 5 seconds to bring everything to
the bottom of the tube. Next, 5 X nucleic acid gel loading buffer (2 [tL) was added to each
sample, and immediately loaded into the gel. New England Biolab's Tri-Dye DNA marker was
loaded with ethidium bromide (0.5 L per lane) in the outermost lanes. The gel was
electrophoresed at 50 V for 2 hours (running at higher voltage caused the RNA to smear).
4-3. Protein Synthesis
Translation or Suppression Reactions (mVASP or nAChR). Translation reactions were
performed using the rabbit reticulocyte lysate translation kit (Promega, Madison, WI) following
manufacturer's instructions. The RNase inhibitor SUPERaseInTM was purchased from Ambion
(Austin, TX).
In general, translation reactions were set up as follows:
Component WT Mutant
DEPC dH2O 15 L 15 - xx tL
Complete amino acids mix 2.5 iL 2.5 [tL
RNase Inhibitor 1.0 L 1.0 [tL
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*deprotected tRNA* -------- 10 g in xx tL
mRNA (2 [tg/pL) 1.5 [L 1.5 [tL
Rabbit Reticulocyte Lysate 30.0 pL 30.0 tL
TOTAL 50.0 [tL 50.0 pL
Each reaction mixture was incubated at 30 C for 2 to 3 hours. If samples were not
immediately purified, they were stored at- 80 °C.
*4PO-tRNA was deprotected by adding equal volume of tRNA to saturated I2 solution in
dH20, and incubating for 10 minutes at 27 C. NVOC-tRNA was deprotected by irradiation with
= 365 nm for 5 minutes (7 mW/cm 2). The deprotected tRNA was at afinal concentration of 2
[tg/[tL. *
Purification of proteins and analysis
nAChR proteins were not purified; analysis was performed as by E. J. P. (CalTech):
PAGE samples were prepared by mixing 10 pL of unpurified rabbit reticulocyte translation mix
with 4 yL 6X SD)S gel loading buffer and diluting to a total volume of 24 pL. Samples were run
at 150 V on a 1% polyacrylamide Readygel (BioRad, Hercules, CA) in X Tris/Glycine/SDS
buffer (OX stock from BioRad). Protein was transferred to nitrocellulose membrane, which was
blocked with 5% milk in 1 X PBS (Irvine Scientific, Santa Ana, CA) with 0.1% (v/v) Tween 20
(Sigma-Aldrich) for hour. The blot was labeled with mouse anti-HA epitope primary antibody
(Covance Research Products, Grand Rapids, MI) for 1 hour at a 1:3000 dilution in the 5% milk
solution. After washing with 3 times X PBS + 0.1% (v/v) Tween 20, the membrane was
labeled for hour with horse radish peroxidase-conjugated goat anti-mouse secondary antibody
(Jackson Immunoresearch Laboratories, West Grove, PA). The blot was washed with 3 times 
X PBS + 0.1% (v/v) Tween 20 and developed with Supersignal West Pico chemiluminescence
reagents from Pierce (Rockford, IL) on Amersham (Buckinghamshire, England) Hyperfilm.
His-tagged mVASP proteins were purified by Method C or D below:
Method C: pH based elution from Ni-NTA resin (buffers stored at 4 °C)
Buffer A: 100 mM NaH2PO4, 2% SDS, 2 mM P-mercaptoethanol, pH 8.0
Buffer B: 50 mM mM NaH2PO4, 150 mM NaC1, 2 mM P-mercaptoethanol, pH 8.0
Buffer C: Buffer B, pH 7.0
Buffer D: Buffer B, pH 4.5
Buffer E: Buffer B, pH 7.0 with 1XBSA
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In all bead steps., liquid was carefully removed with flat gel loading tip:
1. 100 tL Qiagen Ni-NTA agarose beads (50% slurry) was placed in an eppendorf tube
and the liquid removed.
2. Beads were washed 3 x 200 tL Buffer B.
3. 100 tL Buffer A was added to 50 [tL reaction mixture, which was then added to the
beads.
4. Beads were rocked at 4°C for two hours.
5. Spin columns were prepared as follows: 2 columns per reaction
a. Columns: Millipore Ultrafree-MC 30,000 NMWL Filter unit (cat. #
UFC3BTK00); or appropriate MW cutoff concentration columns.
b. Columns were blocked with 300 [tL Buffer E, rocking for 2 hr. at RT.
c. Buffer E was removed by pipette; the columns were washed 3 x 400 [tL Buffer B,
using a pipette.
6. Liquid was removed from beads and saved as "A."
7. Beads were washed with 4 x 100 [tL Buffer C (washes saved as "C").
8. 100 FL Buffer D was added to beads and rocked at 4 °C or RT for two hours.
9. Buffer 1) was removed from beads, added to 100 [tL Buffer B, and saved as "D." An
additional 100 FtL Buffer D was added to the beads and rocked at room temperature for
30 minutes.
10. The second Buffer D elution was removed and added to "D."
11. "C" and "D" samples were concentrated as follows: each sample was loaded into a
prepared column, and concentrated for 15 minutes at 4,000 g. Then 1 to 5 minute
increments at 4,000 g were added until 40 tL remained.
12. 6 [tL concentrate was sufficient to load per well of SDS-PAGE to visualize by western
analysis.
Method D: imidazole based elution from Ni-NTA resin (buffers stored at room temperature):
Buffer A: 100 mM NaH2PO4, 300 mM NaCl, 0.2% SDS, pH 7.8
Buffer B: Buffer A with 5 mM imidazole
Buffer C: Buffer A with 300 mM imidazole
Buffer D: Buffer E with 1X BSA (make as needed)
Buffer E: 100 mM NaH2PO4, 300 mM NaCl, pH 7.4
In all bead steps, liquid was carefully removed with flat gel loading tip.
1. 100 L Qiagen Ni-NTA agarose beads (50 % slurry) were placed in an eppendorf tube
and the liquid removed.
2. The beads were washed 3 x 100 [tL Buffer A.
3. 100 [tL Buffer A and 50 tL reaction mixture were added to the beads.
4. The beads were rocked at 4°C for two hours.
5. Spin columns were prepared as follows: 2 columns per reaction
a. Columns: Millipore Ultrafree-MC 30,000 NMWL Filter unit (cat. #
U]FC3BTK00); or appropriate MW cutoff concentration columns.
b. Columns were blocked with 350 [tL Buffer D, rocking for 2 hr. at RT.
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c. Buffer D was removed by pipette; columns were washed 4 x 350 [tL Buffer E,
using a pipette.
6. Liquid was removed from beads and saved as "A."
7. Beads were washed 4 x 200 tL Buffer B (saved washes as "B").
8. 200 L Buffer C was added to the beads and rocked at 4 °C or RT for two hours.
9. Buffer C was removed from beads and saved as "C." An additional 200 [tL Buffer C was
added to beads and rocked at room temperature for 30 minutes.
10. The second Buffer C elution was removed and added to "C."
11. "B" and "C" samples were concentrated as follows: each sample was loaded into a
prepared column, and concentrated for 7 minutes at 4,000 g. Then 1 to 5 minute
increments at 4,000 g were added until 40 [tL remained.
12. 6 [tL concentrate was sufficient per well of an SDS gel to visualize by western analysis.
The translation efficiency of mVASP was analyzed using hand cast 10% SDS-PAGE,
and transferred to nitrocellulose for western blotting. The membrane was blocked with 5% BSA
in Tris Buffered Saline with 0.05% Tween-20 (TBST) overnight. The membrane was probed
with a polyclonal rabbit anti-mVASP primary antibody (Gertler Lab, M. I. T.) for 2 hours at a
1:1000 dilution in TBST. After washing the membrane 4 times with TBST, it was labeled with
an alkaline phosphatase conjugated goat anti-rabbit secondary antibody (Pierce Biotechnology,
Rockford, IL) for 2 hours. The membrane was washed 4 times TBST and visualized using -Step
NBT/BCIP: Nitro-Blue Tetrazolium Chloride/5-Bromo-4-Chloro-3'-Indoylphosphate p-
Toluidine Salt (Pierce Biotechnology, Rockford, IL). Alternatively, the membrane was labeled
for 1 hour with horse radish peroxidase-conjugated goat anti-rabbit secondary antibody
(Upstate). The blot was washed 3 times 1 X PBS + 0.1% (v/v) Tween 20 and developed as for
nAChR.
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Chapter 5
Toward Reconstituting Directional Motility in VASP-null Cells
Portions of this chapter have been published in the Journal of the American Chemical Society as
noted in the text.' Copyright 2005 American Chemical Society. E. James Petersson
(Dougherty Lab, CalTech) produced the data for the caged-mVASP and caged phospho-mVASP
gel shift assay (Figure 5.8).
Introduction
Vasodilator stimulated phosphoprotein (VASP) is a protein of significant interest in cell
migration. It is part of the Ena/VASP family which comprises actin binding proteins that
localize to the actin stress fibers, the tips of filopodia and the lamellipodial leading edge of
migrating fibroblasts.2 Additionally, the Ena/VASP family has been implicated in other actin-
based processes including axon guidance and T cell polarization.3
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Figure 5.1. Ena/VASP activity and protein organization. a) Schematic of the relationship between
Ena/VASP proteins and capping proteins regulating lamellipodial protrusion and whole cell motility.2
b) Domains of the Ena/VASP family of proteins.3 Phosphorylation sites are highlighted as in the key.
The relationship between Ena/VASP proteins and capping proteins is depicted in Figure
5.1 a. The Ena/VASP activity at the leading edge of a migrating cell antagonizes actin capping
protein activity, which results in longer, less branched filaments that cause more protrusion but
less persistence. ]In contrast, reduced Ena/VASP activity at the leading edge of a migrating cell
results in shorter, more branched actin filament networks that cause lower lamellipodial
protrusion and higher lamellipodial persistence, and thus faster whole cell migration speeds.2
Studies have been performed both in vivo and in vitro and suggest three possible mechanisms for
VASP molecular function: anti-capping, anti-branching, and profilin recruitment.3
Serine 153 of murine VASP, mVASP, corresponds to Serl57 in human VASP. VASP
contains three phosphorylation sites (Ser-157, Ser-239, and Thr-278) that are substrates for
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cAMP- and cGMP-dependent serine and threonine kinases (PKA and PKG, respectively) (Figure
5.1b). Serine 157 is preferentially phosphorylated by PKA. The phosphorylation causes an
apparent molecular weight shift on SDS-PAGE from 46 to 50 kDa, suggesting a change in the
secondary structure of the protein.5
In cellular studies, Serl57 is phosphorylated by PKA upon detachment of fibroblasts and
is dephosphorylated transiently during reattachment to fibronectin. Subsequent cell spreading is
observed with synchronous heavy phosphorylation of VASP.3' 6 Furthermore, VASP-analogs
lacking a complementary Ser157 can localize properly in Ena/VASP-null cells but the
hypermotility phenotype cannot be observed, likely because the analog cannot be phosphorylated
by PKA.7 The evidence supports the hypothesis that phosphorylation of Serl57 is crucial to
VASP function and cell motility. What remains unknown is whether phosphorylation at Serl57
during cell movement represents the overall phosphorylation state of VASP within the cell or if
VASP at the leading edge and at focal adhesions is differentially phosphorylated. 3
To complicate matters further, VASP is a protein for which the in vivo phosphorylation
state may not necessarily correspond with that observed in experiments performed in vitro. As
just described, data collected from living cells suggests that VASP function is activated by
phosphorylation. However, actin polymerization assays demonstrate that nonphosphorylated
VASP can antagonize the capping activity of CapZ,8 one of the suggested functions of VASP in
vivo. Therefore., the challenge continues to understand how VASP is spatially and temporally
phosphorylated within the cell during migration and adhesion.
The evolved nonsense suppression method was used to synthesize mVASP-S153cpS
(Chapter 4). With this protein tool, it will be possible to determine if phosphoserine 153 is
sufficient and/or necessary for migrating fibroblast directionality by restoring phospho-mVASP
after spatially controlled uncaging in null cells. Ideally, randomly migrating mVASP-null
fibroblasts on a surface will have no leading edge. After microinjection of caged phospho-
rnVASP, high-end UV can be administered to one edge of a cell to uncage phospho-mVASP,
thus encouraging lamellipodial speed and giving the cell a direction.
Thus far, mVASP-WT (T = wild type) has been translated in rabbit reticulocyte and
wheat germ extracts. Proteins from both sources have been purified and subjected to gel shift
assays. mVASP-S 153cpS has been synthesized in the rabbit reticulocyte extract and subjected to
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gel shift assays. Current efforts involve synthesis of mVASP-S153cpS in wheat germ extract for
the scaled-up production of protein (Chapter 6).
Results and Discussion
5-1. Cloning and Molecular Biology
Initial translation experiments were performed in rabbit reticulocyte extracts. As
explained in Chapter 4, a significant amount of background was observed in western blot
analysis of samples taken directly from reticulocyte in vitro translation reactions because the
secondary antibody was anti-rabbit. Therefore, in order to purify the protein and reduce
background during analysis, a 6XHis-tag (six contiguous histidine residues) was introduced to
the protein.
Initially, the mVASP-WT and mVASP-S153Z genes were cloned into vectors such that
each gene was flanked by a T7 promoter and a C-terminal 6XHis-tag for purification (Figure
5.2). A C-terminal V5 epitope was already installed in the vector and left intact. The His-tag was
chosen for straightforward purification via Ni-NTA resin. The tag was placed on the C-terminus
such that only full-length protein would be purified away from the translation mixture. For
example, proteins that were aberrantly truncated during the translation or that did not efficiently
suppress the stop codon would not contain the His-tag, and would thus be washed away from
efficiently translated protein during purification.
a
Figure 5.2. Plasmid maps of original vectors. a) pcDNA-mVASP-WT-His. b) pcDNA-mVASP-S 153Z-His.
Briefly, the parent pBS-KSII-mVASP-WT vector was mutated to change serine 153 to
the amber stop codon, TAG, via site-directed oligonucleotide mutagenesis. Both the WT and
S153Z genes were cloned out of their respective parent vector by polymerase chain reaction
(PCR) and purified by agarose gel electrophoresis and extraction. The genes were then ligated
into the pDNA3. I /TOPO vector (Invitrogen) which contained the T7 promoter, V5 epitope, and
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6XHis-tag as seen in Figure 5.2. Additionally, the vector has an upstream PCMV promoter that
can be used if the technology is engineered into mammalian cell culture systems (see Chapter 6).
Plasmids containing the insert in the proper direction were identified by restriction digest
screening and confirmed by DNA sequencing. In vitro runoff transcription was performed as in
Chapter 4 to yield the mRNA transcript of each gene.
In the first experiments, the mVASP-WT translation WT S153Z
MW 1 2 3 1 2 3
efficiency was tested in rabbit reticuloctye extracts, and very
little protein was detectable by western blot analysis. After -'-
the protein was purified from the reaction mixture, there were 
40
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was considerably strong translation of the mutant mVASP-
S 153Z (Figure 5.3). Several conditions were tested to evaluate
better translation conditions for the wild type protein:
switching brands of translation systems, attempting several Figure 5.3. Poor translationFigure 5.3. Poor translation
lengths of incubation time, and eluting protein from Ni-NTA efficiency of mVASP-WT-His
but not mVASP-S153Z-His.
beads via pH rather than imidazole. None of the conditions Proteins were translated in rabbitProteins were translated in rabbit
improved the translation efficiency: the mVASP-WT still reticulocyte extracts, run through
Ni-NTA resin, and subjected to
provided little if any translation, while the mVASP-S153Z Western blot analysis with a
polyclonal anti-mVASP
appeared as strong bands in the western blot analyss antibody. Lanes: 1 = diluted flowantibody. Lanes: = diluted flow
In order to determine if full-length mVASP-WT-His was through, 2 = washes, 3 = elution.
being translated at all, several experiments were performed. First, unpurified translation reaction
mixture was probed directly by Western analysis with the primary polyclonal anti-mVASP
antibody, or one of two primary monoclonal antibodies: anti-His6 or anti-V5. The blots
contained the positive control His-mVASP-WT (provided by M. Barzik, Gertler Lab, M. I. T.).
As seen in Figure 5.4a, it appeared that the full mVASP-WT-His was not being translated.
Furthermore, the pcDNA-mVASP-WT-His plasmid was introduced to a transcription/translation
system to ensure that the problem did not stem from the mRNA. Even in this directly coupled
transcription/translation system, the mVASP-WT-His construct did not fully translate (Figure
5.4b).
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Figure 5.4. mVASP-WT-His is not fully translated. a) Translation mixture probed without
purification. b) Transcription/translation mixture probed without purification. Lanes: WT = mVASP-
WT-His from mRNA or plasmid DNA, C = control His-mVASP-WT protein. Nitrocellulose probed
with the following primary antibodies: 1 = polyclonal anti-mVASP antibody, 2 = monoclonal anti-
His6 antibody, 3 = monoclonal anti-V5 antibody.
At this time in the project, it became known that the native C-terminus of mVASP-WT is
vital to its activity and it is rather sensitive to any additional residues. 9 It is likely that the
combination of the V5 epitope and 6XHis tag at the C-terminus was too much bulk for mVASP.
Therefore, two new constructs with N-terminal His-tags were subcloned into the pcDNA/TOPO
vector (Figure 5.5). Briefly, the mVASP genes for the wild type and the truncated mutant were
cloned out of the parent pBS-KSII vectors by PCR with a forward primer extending the N-
terminus with a 6XHis tag and a reverse primer that incorporated a stop codon such that the C-
terminal V5 epitope of the vector would not be translated. The PCR products were purified by
agarose gel electrophoresis and extraction, and then ligated into the pcDNA3.1/TOPO vector.
Plasmids including the insert in the proper direction were identified by restriction digest
screening and confirmed by DNA sequencing. In vitro runoff transcription was performed as in
Chapter 4 to yield the mRNA transcript of each gene.
a
a
Ib
Figure 5.5. Plasmid maps of modified vectors with N-terminal His-tags. a) pcDNA-His-mVASP-WT
and b) pcDNA-His-rnVASP-S153Z.
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The His-mnVASP-WT and His-mVASP-S 153Z transcripts were translated in rabbit
reticulocyte extracts and purified via Ni-NTA resin by pH-based elutions. As seen in Figure 5.6,
both transcripts with N-terminal His-tags translate well in rabbit reticulocyte extract. While the
N-terminal purification tag is not ideal (any aberrant truncated protein or non-suppressed S 153Z
protein will be purified along with the full-length protein), there is no other purification option
that would allow such resolution.
WTr S13Z
MW 1 2 3 1 2 3 Figure 5.6. His-mVASP-WT and His-
60 .... d:: ...... :,t mVASP-S153Z translated and purified.
so i Proteins were translated in rabbit
40 reticulocyte lysate extract and purified
via Ni-NTA beads by pH elutions.
Lanes: 1 = flow through, 2 = washes, 3
25 = elution.
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5-2. Protein Produced in Rabbit Reticulocyte Extract
With the new mVASP constructs, in vitro translation of the WT and S153Z proteins was first
performed in rabbit reticulocyte lysate extract. As seen in Figure 5.6, the wild-type protein
appears as two tight bands in western analysis due to the two phosphorylation states of the
protein.5 The wild-type protein produced by in vitro translation was assessed for native
biochemical behavior. Phosphorylation by cAMP-dependent protein kinase A (PKA) and de-
phosphorylation by X-protein phosphatase (X-Ppase) was tested on the purified protein (Figure
5.7). As expected, the protein demonstrated a positive gel-shift upon treatment with PKA, and a
negative gel-shift upon treatment with -Ppase. Several conditions were tested to ensure
complete phosphorylation by PKA, including extended incubation time and excess ATP; it was
found that incubation for 30 minutes with 1 mM ATP was sufficient for complete
phosphorylation (Figure 5.7, lane 2).
1 2 3 4 5
Figure 5.7. His-rnmVASP-WT produced in rabbit reticulocyte lysate extract treated with PKA or -
PFpase. Lanes: 1 = His-mVASP-WT, 2 = His-mVASP-WT treated with PKA, mM ATP for 30
minutes, 3 = His-mVASP-WT treated with PKA, 1 mM ATP for one hour, 4 = His-mVASP-WT
treated with PKA, 3 mM ATP for 30 minutes, 5 = His-mVASP-WT treated with X-Ppase for 30
minutes.
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Further gel shift experiments were performed on two more variants of mVASP synthesized
by in vitro translation. The His-mVASP-S153Z transcript was suppressed with caged-serine
(protected with the 6-nitroveratryloxycarbonyl group, NVOC)" ° and caged phosphoserine to
synthesize His-n[VASP-S153cS and His-mVASP-S153cpS, respectively (cS = caged serine, cpS
= caged phosphoserine). Both of these proteins were examined in parallel with His-mVASP-WT
protein produced by in vitro translation. As seen in Figure 5.8, His-mVASP-WT migrated as
two bands, unless dephosphorylated by X-Ppase, which caused the characteristic shift down or
phosphorylated by PKA, which caused the characteristic shift up (lanes Al, A2, and A3,
respectively). As an additional control, His-mVASP-WT was irradiated with UV-A ( = 365
nm), treated with X-Ppase and then analyzed to be sure that the light did not cause a change in
band migration. Likewise, with the caging group on the serine hydroxyl group, His-mVASP-
SS153cS migrated as the unphosphorylated species in the absence or presence of PKA (lanes B2
and B 1, respectively). Upon uncaging with high-end UV light, the serine hydroxyl group was
liberated, and the subsequent phosphorylation by PKA caused the protein to migrate as the
phosphorylated species (lane B3). Finally, the His-mVASP-S153cpS was evaluated by this gel
shift assay. The full-length protein with the caged-phosphoserine migrated as the
unphosphorylated species (lane C). Upon uncaging with high-end UV light, the protein
migrated with the shift characteristic of the phosphorylated species (lane C2). Upon uncaging
and subsequent reaction with -phosphatase, the protein migrated as the unphosphorylated
species (lane C3). Successful production of the caged phosphoserine protein in a rabbit
reticulocyte lysate system was satisfying, and the full-length protein's expected gel shift mobility
wvas particularly encouraging.
A. WT (Ser) B. CSer C. CpSer
hv - + -- -+ 
PKA - - + - + - + - - -
PPase - + -+ --. . . +
pVASP _ _
A1 A2 A3 A4 B1 B2 B3 C1 C2 C3
Figure 5.8. Gel shift assay of His-mVASP proteins produced by in vitro translation.' Lanes: Al = His-
rnVASP-WT, A2 = His-mVASP-WT treated with k-Ppase, A3 = His-mVASP-WT treated with PKA,
A4 = His-mVASP-WT, irradiated then treated with X-Ppase; B1 = His-mVASP-S153cS treated with
PKA, B2 = His-mVASP-S153cS, B3 = His-mVASP-S153cS, irradiated then treated with PKA; C =
His-mVASP-S 153cpS, C2 = His-mVASP-S 153cpS, irradiated, C3 = His-mVASP-S 153cpS, irradiated
then treated with k-Ppase.
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5-3. Protein Produced in Wheat Germ Extract
To further the caged phospho-mVASP experiments, a significant amount of protein was
needed for biological assays. As described in Chapter 4, rabbit reticulocyte lysate systems are not
amenable to large scale production; however, wheat germ systems are eukaryotic and have the
potential to be prepared and used on large scales. Therefore, the N-terminal His-tagged proteins
were translated in wheat germ extract.
First, the His-mVASP-WT and His-mVASP-S153Z transcripts were translated on
analytical scales (50 [tL) and subsequently purified from the reaction mixtures via Ni-NTA resin.
The pH-based elutions from the resin used to purify protein from the rabbit system did not work
well with the wheat germ system. Therefore, two imidazole elution procedures were tested: one
with, and one without, SDS as a blocking agent. As seen in Figure 5.9, both systems were used
successfully to purify the proteins from the wheat germ extract. Furthermore, the strong
translation of the mammalian protein in the wheat germ extract demonstrates that there were no
rare codon complications for this protein (see Chapter 4). This observation is extremely
encouraging for the prospect of future scale-up production.
a b
1 2 3 4 5 6 7
Figure 5.9. Purification via Ni-NTA resin of His-mVASP-WT translated in wheat germ extract. a)
purified with imidazole/SDS and b) purified with imidazole, no SDS. Lanes: 1 = crude, 2 = flow
through, 3 = wash, 4 = elution, 5 = crude, 6 = wash, 7 = elution.
To ensure that the protein produced in wheat germ extract behaves as the protein
produced in the rabbit reticulocyte lysate extract, the same set of gel shift experiments were
performed with purified WVVT protein. As seen in Figure 5.10, His-mVASP-WT does migrate as
expected. Treatment with PKA causes the protein to migrate as the phosphorylated species,
while treatment with X-Ppase causes the protein to migrate as the unphosphorylated species
(Lanes 2 and 3, respectively).
};i:\'''~ ..... Figure 5.10. His-mVASP-WT translated in wheat germ extract
; ~ .........: treated with PKA or k-Ppase. Lanes: 1 = His-mVASP-WT, 2 =
His-mVASP-WT treated with PKA, 1 mM ATP for 30 minutes, 31'~ X~~ 2: ;~ '~; 3= His-mVASP-WT treated with X-Ppase for 30 minutes.
1 2 3
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5-4. Future Direction
The mVASP portion of the caged phosphoprotein project is very much a work in
progress. Several experiments are desired with the caged phosphoprotein, including actin
polymerization and binding partner assays in vitro and the ultimate microinjection studies in
mVASP-null cells in vivo. In order to generate a significant amount of protein for these
biochemical assays and microinjection experiments, a significant production scale increase is
requisite. Toward this end, following establishing consistent suppression reactions in wheat
germ on the analytical scale, a new commercially available system for large-scale protein
translation in wheat germ extract will be utilized to produce His-mVASP-WT and His-mVASP-
S 153cpS. Further discussion can be found in Chapter 6.
Conclusion
The mVASP-WT protein was successfully produced by in vitro translation in rabbit or
wheat germ derived systems. Proteins from both sources were subjected to gel shift assays to
ensure that the proteins can be phosphorylated and de-phosphorylated as described in the
literature.5 Furthermore, the mVASP-S153cpS protein was successfully synthesized in the rabbit
reticulocyte lysate system. Gel shift assays confirm that uncaging yields the phosphorylated
protein, and further treatment with X-Ppase dephosphorylates the uncaged phosphoprotein.
Experimental
5-0. General Procedures
All handling of RNA was performed as described in Chapter 4.
5-1. Cloning and Molecular Biology
The vectors pcDNA-His-mVASP-WT and pcDNA-His-mVASP-S153Z were cloned as
described in Chapter 4. All mRNA was transcribed, purified, and analyzed as in Chapter 4.
Translation reactions in rabbit reticulocyte lysate extract were performed and proteins purified as
described in Chapter 4.
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5-2. Protein Produced in Rabbit Reticulocyte Extract
Translation and suppression experiments were performed as described in Chapter 4.
Proteins were purified from translation mixtures as in Chapter 4, Method C (pH-based elution).
PKA/k-Ppase experiments. Biochemical experiments with in vitro translated His-
mVASP-WT, -S 153cS, or -S 153cpS were performed as follows:
Phosphorylation:
5 pL purified/concentrated sample protein
10 pL dH 2 O
2 OL 0 mM ATP
2 FL 10 X PKA buffer
I L PKA (protein kinase A, New England Biolabs; 2500 U/ gL)
20 gxL total
The reaction was incubated for 30 minutes at 30 C. The reaction was quenched with 5
ML 5X gel loading buffer, and the entire sample was loaded onto SDS-PAGE.
De-phosphorylation:
5 FL purified/concentrated sample protein
11 1 L dH 2 O
2 L 20 mM MnCl 2
2 pL lOX X -Ppase buffer
0.5 VL k-Ppase (lambda phosphatase, New England Biolabs; 400 U/ FL)
20.5 pL total
The reaction was incubated for 30 minutes at 30 °C. The reaction was quenched with 5
jiL 5X gel loading buffer, and the entire sample was loaded onto SDS-PAGE.
Uncaging: Uncaging of protein was performed in purification elution buffer containing
at least 2mM dithiothreitol (DTT). The protein in buffer was placed in a clear walled microfuge
tube, and exposed to k = 365 nm (7 mW/cm 2) for 5 to 10 minutes. The uncaged protein was
uised immediately in experiments.
5-3. Protein Produced in Wheat Germ Extract
Translation with Wheat Germ Extract
For analytical scale translations, the Promega Wheat Germ Extract, Nuclease Treated
(catalog #L4380), was used. The mRNA must be denatured before running the reaction: the
nmRNA was added to the DEPC dH2O, and heated to 67 °C for 10 minutes. Meanwhile, the
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remaining components were assembled. After the mRNA was cooled on ice for 2 minutes, it
was added the remaining components to begin the reaction:
Component Wild Type mRNA
DEPC dH2 0 17.0 - xx tL
Complete amino acids mixture 6.0 p.L
RNAse Inhibitor 1.0 [tL
Potassium Acetate (1M) 1.0 tL
mRNA (5.0 Rg) xx RL
Rabbit Reticulocyte Lysate 25 FL
Total 50 [tL
The mixture was incubated at 25 °C for 2 hours (reactions were placed in a warm room to
ensure that they were held at 25 °C). Reactions were cooled on ice to stop reaction. Proteins
were purified as described in Chapter 4, Method D (imidazole-based elutions). Note that the
imidazole should be removed before photochemical experiments.
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Chapter 6
Conclusions and Future Directions
Conclusions
Caged phosphopeptides and phosphoproteins afford a researcher spatial and temporal
control over the release of the corresponding biologically active species within a living system.
The synthesis and application of these chemical probes have been developed and detailed within
this thesis. Two methods to synthesize 1-(2-nitrophenyl)ethyl caged phosphopeptides have been
described (Chapter 2). These peptides demonstrated good quantum yields of uncaging as
compared to literature values of other ortho-nitrobenzyl derived caged compounds. A seminal
study in which these caged phosphopeptide tools yielded information about the 14-3-3 family's
involvement in cell cycle control was discussed in detail (Chapter 3). The development of the
synthesis that allowed the extension of the nonsense codon suppression methodology to include
caged phosphoproteins was described (Chapter 4). The three most commonly phosphorylated
amino acids (serine, threonine, and tyrosine) were each incorporated into the test protein nAChR
in their caged phosphorylated form, and caged phosphoserine was incorporated into position 153
of mVASP for future biological studies. Finally, the progress toward application of caged
phospho-mVASP in live cell assays was also discussed (Chapter 5).
The ability to study the phenotypic effect of a phosphorylation event in real time gives
scientists some of the essential pieces of information necessary to solve the magnificent puzzle
that is cell signaling networks. The continued evolution of the versatility and accessibility of
these probes will provide the opportunity for a larger impact on studying phosphorylation in
cellular signaling networks.
Future Directions
The caged phosphopeptide and phosphoprotein project has ample room to grow: from
continued work with mVASP to further development of the site-directed incorporation of
nonnatural amino acids. In particular, because the mVASP portion of the project is in early
stages with promising results, it will be at the forefront of continuing research. After assuring
that caged phosphoserine can be incorporated into mVASP consistently on an analytical scale in
the wheat germ system, scale-up production will be established. Once larger amounts of caged
phosphoprotein are available, several experiments can be performed to test the hypothesis that
the phosphoserine 153 is the residue in mVASP critical for lamellipodial formation in cells.
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These experiments will include actin polymerization assays and binding partner experiments in
vitro, and microinjection into mVASP-null cells for uncaging in vivo.
Other aspects of the caged phosphoprotein project can extend in various directions. To
further develop these types of probes at the chemical end, new phosphate analogs may be
synthesized as their caged derivatives and incorporated into peptides or full-length protein via
the adapted suppression methodology (i.e., caged phosphono- or caged thiophospho-amino
acids). With the chemistry and molecular biology techniques unique to the nonsense codon
suppression methodology established within the lab, other non-natural amino acids may also be
incorporated into full-length protein (i.e., 6-N,N-Dimethylamino-2,3-naphthalimide, 6-DMN, G.
Loving). Furthermore, the incorporation of non-natural amino acids may be accomplished in live
mammalian cell culture systems. Recent literature reports demonstrate the ability to use the
import of amino-acylated suppressor tRNA for the site-specific insertion of amino acid
analogues into proteins in mammalian cell culture.' As this time, protein produced in this manner
has been analyzed within cell lysates. Future experiments may involve studying the protein
within the cells themselves. The availability of this type of system will enable structure-function
studies in vivo such as protein-protein interactions, protein localization, etc., through the use of
amino acid analogues that carry photo-activatable groups, fluorescent groups, or other
chemically reactive probes.'
Another potential endeavor in the realm of the nonsense codon suppression methodology
would be the development of a suppressor tRNA that is more compatible with negatively
charged amino acids. As mentioned in Chapter 4, it is likely that the thermodynamic balance
among the backbone of the acceptor and T helices of the tRNA, the amino acid, and the
elongation factors involved in polypeptide elongation is offset with a TH73G tRNACUA acylated
with a negatively charged amino acid.2'3 Therefore, the evolution of a suppressor tRNA that can
accommodate negatively charged artificial amino acids would benefit many researchers working
to employ this methodology with unique chemical probes.
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Appendix
NMR spectra and select HPLC traces
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